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 Thesis Abstract 
 
This thesis focuses on monocyte subsets and furthers the understanding of monocyte subset 
relationships to the atherosclerotic disease process, particularly carotid disease (CD) in 
patients with documented coronary artery disease (CAD).  A literature review of monocytes 
in angiogenesis is presented, revealing a substantial amount of evidence linking monocytes 
with the angiogenic process. A novel agreeable method of performing carotid contrast 
ultrasound (CEUS) for the detection of carotid plaque neovascularisation is presented. CEUS 
is used in those with varying CD and pre-existing CAD to detect the presence of 
neovascularisation and correlates this with monocyte subset totals determined by flow 
cytometry/ enzyme-linked immunosorbent assay (ELISA).  
Levels of three functional monocyte subsets ((CD14++CD16-CCR2+ (Mon1), 
CD14++CD16+CCR2+ (Mon2) and CD14+CD16++CCR2- (Mon3)), and expression of their 
receptors linked to inflammation (toll like receptor (TLR4)), angiogenesis (vascular 
endothelial growth factor (VEGF), tyrosine kinase receptor (Tie2)), and migration 
(chemokine receptor (CXCR4)) are compared with severity of CD by division into 4 groups 
(each with 40 patients); grp.1= CD>50% with pre-existing CAD, grp.2= CD<50% with pre-
existing CAD, grp.3=hypercholesterolemia (HC) patients, grp.4= normocholesterolaemic 
(NC) patients. Mon1 levels were increased with severity of CD, and found to be predictive in 
those patients with increased carotid intima media thickness, a marker of systemic 
atherosclerosis. Mon3 known to be increased in stable CAD, was shown to be increased in 
those with moderate carotid disease but not in the presence of severe disease. All monocyte 
subsets were shown to demonstrate varying levels of receptor expression mediating the 
pathological processes occurring at atherosclerotic plaque. 
 Finally pre and post levels of monocytes where taken on patients after cessation of statin 
therapy for two weeks. Cessation of statin therapy did not affect monocyte subset counts but 
caused a reduction in both TLR4 and CXCR4 expression on Mon1. This further advances 
one’s knowledge of statin’s complicated characteristics.  
This thesis attempts to expand one’s understanding of the behavioral heterogeneity of 
monocytes in atherosclerotic disease and demonstrates CEUS as a feasible research imaging 
method to address key questions in the field.  
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CHAPTER I. INTRODUCTION 
 
1.1. Monocytes and angiogenesis 
 
1.1.1. Introduction 
 
Atherosclerosis is the primary cause for stroke and coronary artery disease in the 
Western World.(Li and Glass, 2002) It is a chronic inflammatory process 
characterised by development of lipid rich plaques within the layers of the arterial 
wall.  
 
Figure 1: Angiogenesis and inflammation occurring with the arterial wall/vessel. 
VEGF, vascular endothelial growth factor  
  
Within this thickened wall is where foam cells, monocyte derived lipid laden 
macrophages have been recognised.(Glass and Witztum, 2001) The formation of 
Intraplaque vessel         
plaque 
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atherosclerotic plaque is a series of events that is initiated with lipid accumulation 
(fatty streak) followed by monocyte infiltration and the lipid core formation. 
Advanced lesions can obstruct arterial lumen, but at any stage atherosclerotic plaque 
may be complicated by rupture causing a hypoxia/ischemia of the downstream tissues 
and subsequent vascular complications.  
 
Unhealthy lifestyles, diabetes, obesity, hypertension are still common contributors to 
the atherogenesis and development of unfavourable events thus prompting 
identification of new therapeutic targets.(Cannon, 2007) This is particularly true as 
current treatment modalities such not all patients are suitable for adequate coronary 
artery bypass grafting or angioplasty.(Zbinden et al., 2005) Of interest, each of the 
risk factors above triggers numerous pathological pathways involving a number of 
molecular processes, which include lipid metabolism, coagulation, apoptosis, 
hypoxia, and the immune response.(Ferrara, 1999, Helisch and Schaper, 2000, Henry 
et al., 2003) 
 
The body’s natural response to ischemia is a reparative mechanism summarised by 
the term neovascularisation. Neovascularisation includes three processes: 
angiogenesis, arterogenesis, and vasculogenesis.(Beem, 2008) The formation of new 
capillary vessels, angiogenesis has been extensively researched and occur in response 
to a hypoxic environment.(Luque et al., 2009, Bjornheden et al., 1999) Progression 
and expansion of already existing collateral smooth muscle-type vessels or 
arterogenesis, is believed to be a mechanism of organ preservation in the presence of 
vascular occlusion. Vasculogenesis or new vessel growth derived from 
progenitor/stem cells has been demonstrated in both the adult and embryo.(Silvestre 
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et al., 2008, Beem, 2008) Understanding these processes of vessel adaptation or 
formation is fundamental for developing new therapeutic strategies. 
 
Inflammation has been shown to be an essential factor accompanying both the 
angiogenic and atherogenic pathways.(Silvestre et al., 2008) Monocyte-derived 
macrophages play a pivotal role in lipid deposition and progression of atherosclerosis, 
but they are also implicated in the genesis of new vessels.(Li and Glass, 2002) The 
aim of my first thesis chapter is to present an overview of the available evidence 
supporting the role of monocytes in angiogenesis. 
 
1.1.2. Search Strategy 
 
I searched the following electronic databases (limiting the search from 1970 up to 
July 2012): PubMed, Medline, EMBASE and Cochrane Reviews. Given the enormity 
of this subject area, I have focused on areas of particular relevance to angiogenesis 
and the role of monocytes in neovascularisation. Multiple formal systematic searches 
were performed with the aid of a clinical librarian and in accordance with accepted 
PRISMA guidelines (Appendix 1) to identify relevant publications. The key words 
used in combinations starting with the stem of monocyte AND angiogenesis then 
followed by the terms, (again due to the enormity of the subject matter) were: 
monocyte subsets, neovascularisation, vasculogenesis, angiopoietin, vascular 
endothelial growth factor (VEGF), Tie2, basic fibroblast growth factor (βFGF), beta 
adrenergic system, endothelial progenitor cells, hypoxia inducible factors, interleukin, 
tumour necrosis factor (TnF), vascular adhesion molecule (VCAM), intracellular 
adhesion molecule (ICAM), monocyte chemoattractant protein (MCP).  
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The aim of this process was to provide background information and highlight recent 
advances in the subject matter, for my thesis. Full text articles where available 
electronically were then obtained from the National Electronic Library for Health 
(NELH) and from the University of Birmingham Library. 
 
The first search on monocytes and angiogenesis identified 1414 citations. 
Furthermore with a combination of terms starting with the stem as mentioned above 
an additional 518 citations were identified. Myself, and other members of our unit, 
reviewing monocytes and the angiogenic processes, reviewed these citations. (Tapp, 
2011, Shantsila, 2007, Wrigley, 2011) All abstracts were read if available, if not, full 
texts were obtained. Publications focusing on monocytes, their subsets and surface 
markers were ordered in full text. This totalled 104 articles. Reasons for exclusion of 
identified literature included: animal studies, articles unavailable, and non-English 
languages.  
 
The second search, focused on carotid disease and carotid contrast ultrasound. The 
search terms used in combination were; carotid stenosis, contrast ultrasound, 
neovascularization. This search revealed, 1346 citations. (Appendix 2) These 
publication abstracts were all read, and full texts were obtained if the abstract was not 
available or uncertainty of relevance on reading the abstract. Relevance was agreed 
with my research supervisors. Reference lists of all articles were searched for further 
literature. Articles not related to carotid contrast ultrasound were excluded. At the end 
of this process 22 papers were referenced for this part of the thesis.  
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In the search of literature on related to the role of statins in monocyte function, terms 
used in permutation starting with the stem statin were: coronary artery disease, 
monocyte subsets, and monocytes. Citations not directly related to topic of the search 
were excluded. This identified 638 citations. Again all abstracts were read, and full 
articles were obtained when abstracts were not available or the abstracts were unclear. 
Relevance was agreed with my supervisors. This resulted in 35 papers used for 
referencing in this section of my thesis. 
 
All articles from all sections once deemed to be relevant were read, classified by 
subject or publication type and a database compiled using referencing software.  
 
1.1.3. Atherogenesis and plaque neovascularisation 
 
Atherosclerosis is characterised by monocyte adherence to endothelium cell, 
migration into the arterial wall, and lipid accumulation.(Pietsch et al., 1996) The 
earliest detectable atherosclerotic change is pathological intimal thickening.(de Groot 
et al., 2008, Lorenz et al., 2007) 
Enlargement of the plaque, results in intraplaque hypoxia that triggers the 
inflammatory cell infiltration, thus promoting local neovascularisation.(Kwon et al., 
1998) Interestingly, although intimal thickening is believed to be an early surrogate 
marker for atherosclerosis, pathological neovascularisation is implicated in both early 
and late stages of the disease.(Kwon et al., 1998) For example, in experimental 
studies on hypercholesterolemia, adventitial neovascularisation in the coronary 
arteries has been shown to be present even before the actual plaque (protrusion into 
the lumen) begins to develop.(Kwon et al., 1998) Two instrumental factors 
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influencing the initiation of intra-arterial neovascularisation appear to be (i) local 
ischemia, and (ii) either local or systemic inflammatory burden.(Khurana et al., 2005, 
Doyle and Caplice, 2007, Moulton et al., 2003) Pathological thickening of the intima 
greater than 100μl increases the distance between the lumen and the inner parts of the 
vascular wall thus impairing the supply with oxygen and nutrition.(Magnoni et al., 
2009) As vascular disease ensures excessive vessel wall thickness, proliferation of the 
vasa vasorum and intimal neovascularisation is observed. Indeed, the degree of 
adventitial neovascularisation has recently been demonstrated to be associated with 
intimal media thickness.(Magnoni et al., 2009) 
 
Evidence of the role of ischemia in the initiation of angiogenesis stems from the 
demonstration of increased levels of hypoxia inducible factor (HIF-1), which 
ultimately promotes VEGF production.(Bjornheden et al., 1999, Beem, 2008, 
Kuwahara et al., 2002) As a potent stimulator of angiogenesis, VEGF is consequently 
able to create a local proangiogenic environment by mobilising endothelial progenitor 
cells (EPCs). (Inoue et al., 1998)  
Table 1: Angiogenesis inhibitors and stimulators 
Stimulators Inhibitors 
VEGF Angiostatin 
IL6 TGF-β 
TNF Interferon 
bFGF IL12 
PDGF Anti-thrombin III 
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bFGF, basic fibroblast growth factor; IL, interleukin; PDGF, platelet derived growth factor; TGF, 
transforming growth factor; TNF, tumour necrosis factor; VEGF, vascular endothelial growth factor. 
 
Furthermore, aggressive plaque development and accelerated neovascularisation of 
the vascular wall have been seen following the administration of VEGF in laboratory 
experiments.(Celletti, 2001) 
 
Hypoxia-independent pathways triggered by an inflammatory stimulus within the 
vascular wall have also been recognised as modulators of angiogenesis.(Carmeliet, 
2003) The density of intra-plaque vessels corresponds to the focal accumulation of 
inflammatory cells (i.e., monocytes/macrophages) forming a pathological circle: 
angiogenesis – mobilization of inflammatory cells – angiogenesis.(Moulton et al., 
2003) Switching between this inflammatory/angiogenic cascade may be responsible 
for enhanced plaque progression related to local plaque inflammation and plaque 
destabilisation. This hypothesis is supported by increased expression of leukocyte 
adhesion molecules, such as vascular adhesion molecule (VCAM-1) and intracellular 
adhesion molecule (ICAM-1), on the intimal side of vascular endothelium as opposed 
to the adventitial side.(O'Brien et al., 1996) Therefore, these observations allude to the 
notion that the presence of these adhesion molecules on the newly formed vessels is 
associated with the enhanced accumulation of leukocytes.(O'Brien et al., 1996) 
 
Whilst association of the development and progression of atherosclerosis with 
macrophages has long been recognised, the function of their blood ancestors, 
monocytes was less addressed. However, a potential link between monocytes and 
abnormal plaque angiogenesis has a strong biological justification. Prior to discussing 
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angiogenesis, an overall understanding of vasculogenesis (new-vessel formation), and 
its relationship to EPC’s needs to be addressed. 
 
1.1.4. Vasculogenesis 
 
Vascular system development in the embryo is termed, vasculogenesis. The first 
endothelial and haematopoietic cells are derived from a process whereby blood 
islands are formed from haemangioblasts, otherwise known as mesodermal 
progenitors in the embryonic yolk sac.(Beem, 2008) These islands of cells 
differentiate and proliferate form precursors of the vascular wall, angioblasts, which 
further give origin to endothelial cells.(Beem, 2008, Risau, 1997) Vascular 
development occurs, as these endothelial cells form the first primitive tubes/vessels. 
Importantly, it is at this point when both VEGF and basic fibroblast growth factor 
(bFGF, a critical angiogenic factor), starts to play a role in the process.(Beem, 2008, 
Tomanek et al., 2001) Activation of bFGF receptors on endothelial cells by bFGF 
increases the endothelial cell motility, proliferation and proteinase activity.(Beem, 
2008, Reiland and Rapraeger, 1993, Klagsbrun, 1992, Mignatti et al., 2007) bFGF can 
also induce VEGF expression via HIF-1α activation as seen in a study by Shi et al., 
who showed that HIF-1α induction by bFGF seemed to be an independent pathway 
triggering VEGF expression in breast cancer.(Hata et al., 1999, Shi et al., 2005) 
Bovine studies have shown endothelial cell proliferation and capillary formation in 
the presence of bFGF and VEGF.(Goto et al., 1993) 
 
The identification of EPCs in the adult has led to efforts to understand their 
contribution to the adult angiogenic processes. However, it must be mentioned that 
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there is much debate regarding methods of EPC quantification and standardisations. 
This is due to a significant cell overlap observed and the presence of the progenitors 
at different stages of maturation.(Schmidt-Lucke et al., 2010, Beem, 2008) Recently 
Sozer and colleagues have demonstrated that monocytes and EPCs share many 
characteristics whilst other less differentiated primitive cells produce endothelial cells 
only in vitro.(Sozer et al., 2008) Further delineation of their phenotype is 
required.(Beem, 2008) 
 
1.1.5. Angiogenesis 
 
The development of new vasculature, particularly the formation of new capillaries 
from endothelial cells that “sprout” from existing blood vessels is of importance for a 
number of pathological and homeostatic processes. It is also fundamental for the 
embryonic development.(Willems, 2009) Tumour research, the important field for 
angiogenic studies, has not only suggested a pathological significance of the 
angiogenic process in cancer but it has led to further efforts to investigate these 
processes in biological mechanisms of wound healing, ovulation, and tissue 
repair.(Johnstone and Farley, 2005, Tonnesen et al., 2000) 
 
Naturally healthy tissue requires a supply of nutrients and oxygen. Also the 
restoration of tissue under ischaemic conditions and tumour growth are dependent on 
new vessel formation for the supply of nutrients and the removal of degradation 
products.(Beem, 2008) This understanding of an angiogenic process has led to a vast 
number of studies on therapeutic approaches to the management of vascular disorders. 
The primary pathological focus of this evidence has been on understanding the 
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atherosclerosis-related angiogenesis in plaque formation, and the inhibition of 
neovascularisation thereby attempting to slow the disease progression.  
 
Interestingly, the main laboratory approach used for understanding of the mechanisms 
of atherosclerosis-related angiogenesis was based on analysis of ischemic tissues in 
the presence of pre-existing plaque stenosis as opposed to long-term studies on the 
development and progression of the disease. For example, a study by McCarthy et al 
suggested an association between symptomatic carotid disease (plaque) and the 
presence of intra-plaque neovascularisation.(McCarthy et al., 1999) However this 
study recruited patients who had pre-existing carotid stenosis and did not study 
patients who were initially carotid plaque free and developed stenosis over a number 
of years.(McCarthy et al., 1999) This lack of evidence on early changes and 
pathological mechanisms has driven the need for non-invasive approaches to detect 
neovascularisation, such as carotid contrast ultrasonography.  
 
The initiating factor of angiogenesis is a hypoxic environment, often associated with 
tissue inflammation.(Bosco et al., 2008) The entire pathway is thought to be 
stimulated by HIF-1α.(Kimura and Esumi, 2003, Bos et al., 2005) In the ischemic 
environment HIF-1α, escapes degradation due to its transcription being down 
regulated and its ability to bind other factors (e.g., HIF-1β) activating target genes 
involved in angiogenesis.(Beem, 2008, Kimura and Esumi, 2003) Interestingly a 
number of growth factors (e.g., platelet-derived growth factor [PDGF], and bFGF) 
also share this regulatory hypoxic driven pathway.(Atkinson and Fox, 2004) VEGF, 
an essential angiogenic modulator has been shown in several in vivo models to induce 
a strong concomitant angiogenic cascade with HIF-1.(Kuwahara et al., 2002, 
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Pellizzaro, 2002) VEGF expressed by macrophages and T-lymphocytes stimulates 
endothelial cells to produce monocyte chemo-attractant protein (MCP-1) hence 
attracting monocytes and enhancing cell migration by increasing the permeability of 
the endothelial layer.(Melter et al., 2000, Hong et al., 2005) Dvorak et al. have 
demonstrated the presence of immature vessels with increased vascular leakage after 
the addition of VEGF in animal experiments.(Dvorak et al., 1995) Embryologically, 
the absence of VEGF results in early death due to abnormal blood vessel growth, 
demonstrating a common link between the physiological and pathological angiogenic 
pathways.(Carmeliet et al., 1996) 
 
The sprouting of new vessels from pre-existing vasculature is known as 
angiogenesis.(Ojeifo et al., 1995, le Noble et al., 1998) Angiogenic signals from 
surrounding cells lead to vasodilatation and an increase in vascular 
permeability.(Beem, 2008, Kimura and Esumi, 2003, Pamukcu et al., 2010, Wu et al., 
2009) Digestive enzymes such as collagenase and matrix metalloproteinases (MMPs) 
partially destroy the basement membrane.(Beem, 2008, Folkman and Klagsbrun, 
1987, Sengupta and MacDonald, 2007) The plasma proteins then form a fibrin rich 
matrix, with a lumen forming in the proliferating capillary when the activated 
endothelial cells migrate towards the site.(Ojeifo et al., 1995) Ultimately, the newly 
formed capillaries become part of the existing circulation in a process in which shear 
stress is a critical factor.(Marumo et al., 1999) 
 
Although inflammation plays a significant role in angiogenesis, multiple other 
processes are implicated in development of new vessels, including cell-to-
extracellular matrix interactions, vascular wall maturation and basal lamina 
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modifications.(Pamukcu et al., 2010, Hoefer et al., 2004) The behaviour of 
endothelial cells is significantly influenced by inflammatory leukocytes able to 
release the number of pro-angiogenic factors, such as VEGF, hepatocyte growth 
factor (HGF), tumour necrosis factor-α (TNFα), and interleukin (IL)-8.(Hoeben et al., 
2004, Ding et al., 2004, Ding et al., 2003, Hoefer et al., 2002, Li et al., 2003) 
 
In areas of atherogenic lesions chronic infection, cigarette smoking, free radicals, 
hypertension, and diabetes have all been implicated as causes in the activation of 
endothelial cells.(Marumo et al., 1999, Ross, 1999, Osterud and Bjorklid, 2003) The 
increased shear stress acting through both membrane structures and cell junction 
molecules, stimulate quiescent endothelial cells lining the vascular wall.(Resnick et 
al., 2003) This intracellular signalling triggers the expression of genes like MCP-1 
mRNA, involved in induction of transcription factors responsible for shear stress-
mediated effects.(Ojeifo et al., 1995, Pamukcu et al., 2010, Chien et al., 1998) This 
sequence of events in the presence of hypercholesterolemia triggers expression of 
adhesion molecules, particularly P-selectin, E-selectin, VCAM-1, ICAM-1, as well as 
MCP-1 release and activation of genes responsible for the expression of chemokine 
receptor 2 ((CCR2) (MCP-1 receptor).(Pamukcu et al., 2010, Wu et al., 2009, Sadhu 
et al., 2007, Ohno et al., 1995) 
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1.1.6. Monocytes in angiogenesis  
Oxygen-deprived intima of the arterial wall recruits circulating monocytes via 
specific integrin receptors (Mac-1) that interact with the endothelial adhesion 
molecules.(Hoefer et al., 2004, Schuler et al., 2003, van Weel et al., 2007)  
 
Figure 4: Monocytes role in angiogenesis.  
HIF, hypoxia induced factor, VEGF, vascular endothelial growth factor, MMP, Matrix 
metalloproteinase, Ang, Angiopoietin, Tie, Tyrosine Kinase, PDGF, Platelet derived growth factor, 
MCP, Monocyte chemotactic protein, MAC, Macrophage antigen, LDL, Low density lipoprotein.
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Hajjar et al. have shown that this binding predominantly occurs at the tight junctions 
of the endothelial cells and allows monocyte entry into the sub-endothelial 
space.(Hajjar and Nicholson, 1995) VEGF, expressed by macrophages activates the 
production of MCP-1 by the endothelial cells and an increase in the permeability of 
the endothelial layer. (Marumo et al., 1999)  
 
Table 2: Examples of animal and human studies implicating monocytes in 
angiogenesis. 
Study Model Mediating 
factor 
Study design Study finding 
(Capoccia 
et al., 
2008) 
Mouse MCP-1  
 
Direct injection of bone marrow 
cells into blood of surgically induced 
hind limb ischaemia. Adductor hind 
leg muscle was then subjected to 
flow cytometry, ELISA, and 
immunofluorescence. Bone marrow 
cells were also harvested and 
transplanted into wild type mice. 
Inflammatory subset of 
monocytes was selectively 
recruited to the site of insult in 
parallel with increased MCP-1 
amounts.  Two waves of 
monocyte proliferation were 
demonstrated in the presence of 
angiogenesis and inflammation. 
(Arras et 
al., 1998) 
Rabbit TNF,  
bFGF  
 
Femoral artery occlusion of rabbit 
hind limb for 3 and 7 days, with 
randomly given lipopolysaccharide. 
Further control animals were tested 
at 21 days for comparison. Carotid 
artery catheters were also placed for 
proliferation analysis.  
After day 7 of induced hypoxia, 
maximal macrophage 
proliferation was present being 
associated with higher TNF and 
bFGF levels. 
Monocytes/macrophage 
activation played important 
role in angiogenesis and vessel 
growth in the presence of 
hypoxia. 
(Hong et 
al., 2005) 
Rat, 
Chick 
MCP-1,  
VEGF 
 
Thoracic and abdominal aortas were 
obtained from 5-week-old rats. 
VEGF was analysed by mRNA 
expression using PCR. MCP-1 was 
analysed in vivo using chick 
chorioallantoic membrane.  
Monocytes were implicated in 
angiogenesis in MCP-1-
mediated manner and related to 
HIF and VEGF-A up-
regulation. 
(Cursiefen 
C et al., 
2004) 
Mouse VEGF Mouse model of suture induced 
inflammatory corneal 
neovascularisation. 
Immunochemistry and morphometry 
were used to analyse angiogenesis in 
the cornea.  
VEGF mediates the recruitment 
of monocytes/macrophages 
resulting in the initiation of 
neovascularisation in the 
presence of inflammation but 
also amplifies the pathological 
process of both angiogenesis.  
(Celletti et 
al., 2001) 
Mouse, 
Rabbit 
VEGF 
 
Cholesterol fed mice were 
administered intra-peritoneal VEGF 
and albumin. Combination of FACS 
analysis and histological section 
were used for blood and plaque 
progression analysis respectively. 
VEGF promoted angiogenesis 
but also played a role in plaque 
progression associated with 
monocyte/macrophage 
accumulation.  
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Plaque formation was also analysed 
in the same manner in rabbit to 
eliminate cross species-specific 
effect.  
(Murdoch 
et al., 
2008) 
Human Tie-2, 
Ang 2 
Flow cytometry and chemotaxis 
micro-chamber technique in healthy 
donors.  
Ang-2 recruited Tie2+ 
monocytes to both tumours and 
sites of inflammation and 
enhanced expression of 
proangiogenic cytokines.  
(Eubank 
TD et al., 
2003) 
Human M-CSF, 
VEGF 
Isolated human monocytes were 
stimulated with M-CSF. ELISA was 
used for VEGF analysis.  
M-CSF enhanced production of 
VEGF and angiogenesis by 
human monocytes.  
(Venneri 
et al., 
2007) 
Human Tie-2 Healthy blood donors and surgically 
resected tumour tissue. Analysis 
performed using flow cytometry, 
western-blot analysis, 
immunohistochemistry and 
migration assays.   
Tie2+ monocytes were 
associated with angiogenesis. 
MCP- monocyte chemotactic protein, VEGF- vascular endothelial growth factor, EC- endothelial cell, 
HIF- hypoxia inducible factor, bFGF- basic fibroblast factor, PCR-polymerase chain reaction, Ang-2- 
Angiopoietin, Tie2 – Tyrosine Kinase, M-CSF- macrophage colony-stimulating factor.  
 
  
The chronic low-grade inflammation inside the vascular wall has been shown to be 
associated with monocyte infiltration. The monocyte maturation to macrophages is 
accompanied by the production of cytokines and growth factors.(Hoefer et al., 2004, 
Hoefer et al., 2002, Arras et al., 1998) 
 
Plaque monocytes/macrophages interact with collagen and proteoglycans in the 
extracellular matrix by expressing proteases like urokinase plasminogen activator (u-
PA).(Menashi et al., 1993) uPA activates plasmin, which in turn degrades the 
extracellular matrix.(Menashi et al., 1993) The monocytes produce PDGF, which 
induces mitotic activity of the endothelial cells and vascular smooth muscle 
cells.(Hoppenreijs, 1994, Polverini et al., 1977) Activated plaque 
monocytes/macrophages ingest the oxidised lipids and become lipid-laden ‘foam’ 
cells. It is believed that ‘foam’ cells promote vascular remodelling by stimulation of 
smooth muscle cell migration and a subsequent shift in endothelial function.(Kruth, 
2001) 
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Whilst there is a distinct relationship between monocytes and angiogenesis in the 
atherosclerotic lesions, controversy surrounds the origin of the native endothelial cells 
as well as the role of specific subtypes of monocyte populations such as 
CD14+/VEGFR-2+ monocytes.(Elsheikh et al., 2005) Animal studies have 
demonstrated that although endothelial cells play a role in the initiation 
atherosclerotic process they themselves may be bone marrow-derived as in tumour-
associated blood vessels.(Nolan et al., 2007) Once monocytes have infiltrated the 
tissue layers a proportion of them will differentiate into dendritic cells triggering the 
activation of antigen specific T lymphocytes associated with creation of the local 
inflammatory environment.(Randolph et al., 1998) 
 
Large proportion of circulating EPCs was found to be of monocytic origin.(Shantsila 
et al., 2007) Human monocytes include a population of cells able to obtain endothelial 
cell phenotype in culture.(Fernandez Pujol et al., 2000) Cultures of so-called ‘early’ 
EPCs are mainly comprised of monocytes and T-cells and their formation is strictly 
dependent upon monocytes presence.(Shantsila and Lip, 2009) Additionally, 
monocytes constitute the dominant population among circulating cells expressing type 
2 receptors for VEGF (VEGFR2).(Romagnani et al., 2005) Cells bearing CD14 (a 
monocyte marker) are capable of improving re-endothelialisation after carotid balloon 
injury in animals and this process depends upon the levels of a major factor 
stimulating monocyte mobilisation, MCP-1.(Fujiyama et al., 2003) Elsheikh et al have 
reported that transplantation of CD14+/VEGFR2+ cells into balloon-injured femoral 
arteries of nude mice significantly contributed to their efficient re-
endothelialisation.(Elsheikh et al., 2005) These data support the possible involvement 
of monocytes in hypoxia-induced VEGF-mediated formation of vasa vasorum.  
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1.1.7. Angiopoietins 
 
Homeostasis of the vascular system is supported by secreted glycoproteins called 
angiopoietins (Ang).(Barton et al., 2005) These angiopoietins function as growth 
factors to aid angiogenesis. However, Metheny-Barlow et al. have shown that his may 
not necessarily be the case for angiopoietin 1 (Ang1), which, under specific 
conditions, may act as an inhibitor of the angiogenic process.(Metheny-Barlow and 
Li, 2003) 
 
There are 4 main ligands in the angiopoietin group (Ang1, Ang2, Ang3, 
Ang4).(Thomas and Augustin, 2009) Ang1 and Ang2 have been well studied and 
have a strong affinity to tyrosine kinase receptors.(Lemieux et al., 2005) Both Ang1 
and Ang2 can be found in high concentration in tumours, particularly angiosarcoma 
suggesting their role in both tumour angiogenesis and progression.(Amo et al., 2004, 
Brown et al., 2000) Shim et al. have demonstrated differences between Ang1 and 
Ang2 in their response to hypoxia. Ang2 was up regulated in the presence of ischemic 
tissue whereas Ang1 was mostly associated with malignancy. However, both are 
implicated in the angiogenic processes.(Shim et al., 2007) The family of receptors, 
which primarily maintains Ang influence and ability to be expressed in endothelial 
cells, is a tyrosine kinase, Tie2. Tie2 is involved in the stabilization of mature blood 
vessels, promoting the interaction between endothelial cells and supporting 
periendothelial cells. (Thurston, 2003) 
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Figure 3:  Interaction of tyrosine kinase receptor type 2 (Tie2) with vascular 
smooth muscle. 
Ang, angiopoietin. 
 
Animal studies have shown that absence of either Ang1 or Tie2 results in incomplete 
vascular development and death.(Suri et al., 1996, Sato et al., 1995) Interestingly, the 
interaction between Tie1 and Tie2 remains primarily unclear but it is known that none 
of the Ang family members directly binds Tie1, yet Tie2 inhibits Tie1-mediated 
regulatory control of endothelial cell function.(Saharinen et al., 2005) 
 
Hauer et al. have demonstrated an overall reduction of experimental atheroma after 
Tie2 inhibition.(Hauer et al., 2009) This again reveals a significant therapeutic 
potential of this pathway. More recently, Wu et al. have shown a relationship between 
both Ang2 and VEGF in genetically modified mouse studies.(Wu and Liu, 2010) 
Although, the angiogenic effects was greater in the lymphatic tissue rather than in 
blood vessels, the studies raised interest in the development in anti-angiogenic 
therapies.(Wu and Liu, 2010) Recently, Saharinen et al. have suggested that the two 
systems (i.e., mediated by VEGF and Ang) played different roles in blood and 
lymphatic vessel growth.(Saharinen et al., 2010) 
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Another study demonstrated not only a link between both VEGF and Ang2 but also a 
clear difference in how they regulated the angiogenic pathways.(Fujiyama et al., 
2001) Indeed, Ang1 has showed an inhibitory role against the actions of Tie2 in blood 
vessel maturation whilst Ang2 expression counteracted this Ang1 effect, thus 
promoting vascular stabilisation.(Hawighorst  Skobe, 2002) Once again this 
antagonist relationship has sparked interest from both a scientific and therapeutic 
point of view. 
 
1.1.8. Vascular endothelial growth factor 
 
MCP-1, although known primarily to play a role in inflammation has been shown to 
be a chemokine with angiogenic properties.(Hong et al., 2005) Hong et al 
demonstrated that the MCP-1-mediated angiogenic cascade is maintained and 
modulated by VEGF.(Hong et al., 2005) Further evidence to this relationship and the 
monocyte role in angiogenesis has been shown by in vitro treatment of human 
monocytes with VEGF obtained from tumour cells, resulting in both monocyte 
activation and migration.(Barleon et al., 1996) 
 
VEGF is a pro-angiogenic growth factor primarily involved in the initiation of new 
capillary formation.(Risau, 1997) VEGF is involved in embryonic angiogenesis but it 
is as well a potent signalling protein, which stimulates vasculogenesis and 
angiogenesis in the presence of injury, exercise, and formation of collaterals.(Prior et 
al., 2004, Miquerol et al., 2000) There are 4 well-known VEGF derivatives plus one 
placental growth factor.  
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Table 3: Family of VEGF and their functions.  
Type Function 
VEGF A Angiogenesis 
 Chemotactic 
 Vasodilatation 
VEGF B Embryonic 
VEGF C Lymphangiogenic 
VEGF D Lung  
Lymphatic’s 
PlGF Vasculogenesis 
PlGF, placental growth factor; VEGF, vascular endothelial growth factor. 
 
 
Figure 4: Family of VEGFs and their functions.  
HIF, hypoxia induced factor, VEGF, vascular endothelial growth factor, VEGFR, vascular endothelial 
growth factor receptor 
 
Interestingly, excessive VEGF expression has been linked to the progression of 
malignancy, and retinal eye disease.(Guo et al., 2010) VEGF main action however, is 
mediated by binding of tyrosine-kinase receptors.(Shibuya et al., 1990) 
 
VEGFR2 are essential for endothelial cell survival.(Kabrun et al., 1997) Absence of 
VEGFR2 is incompatible with development of endothelial and haematopoietic cells in 
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animals.(Matthews et al., 1991) In contrast VEGFR1 is not obligatory for endothelial 
cell differentiation but it is required for embryonic development.(Fong et al., 1995) 
Interestingly, a possible antagonistic relationship between VEGFR1 and VEGFR2 has 
highlighted the intricate relationship between promoting and maintaining vascular 
development in ischemia, cancer, and other pathological processes.(Yancopoulos et 
al., 2000) Unfortunately, despite the primary role of VEGFR2 in both vasculogenesis 
and angiogenesis, the molecular mechanisms controlling its genetic expression are 
still at an early stage of recognition, representing justification for renewed focus in the 
critical process of protein modulation in a therapeutic respect.(Guo et al., 2010) This 
is especially true since it has been demonstrated that tumour genesis itself involves 
specific angiogenic factors based on tumour type.(Hayes et al., 2007) 
 
1.1.9. Monocyte heterogeneity 
 
Monocyte subsets in particular are believed to play a differential role in intra-plaque 
angiogenesis and tissue repair.(Pamukcu et al., 2010) The subsets differ in phenotype, 
granulation, size, morphology and genetic make up.(Yona and Jung, 2010) Over the 
last thirty years, human monocyte subsets were distinguished based on their surface 
CD14/CD16 expression as ‘classical’ CD14++CD16– cells and less frequent ‘non-
classical’ CD14+CD16++ blood monocytes.(Grage-Griebenow et al., 2001) However 
this diversity amongst monocyte subsets is not unique to humans, and has been shown 
in animals.(Chamorro et al., 2005, Ahuja et al., 1995) 
 
A third subset can be distinguished by surface expression of CCR2. (Shantsila et al., 
2011)  
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Table 4: Monocytes subsets and their functions. 
Monocyte subset Expression Primary Function 
Mon1 (classical) CD14++CD16–CCR2+ Phagocytosis 
Cytokine production 
Mon2 (intermediate) CD14++CD16+CCR2+ Angiogenesis 
Mon3 (non-classical) CD14+CD16++CCR2– Collagen deposition, 
Anti-inflammatory effects 
 
 
Interestingly, this CD14++CD16+CCR2+ monocytes phenotypically resemble the 
previously reported pro-angiogenic monocytes.(Shantsila et al., 2011) For example, 
De Palma et al., and Venneri et al. have demonstrated distinct pro-angiogenic 
properties of Tie2-expressing monocytes.(De Palma et al., 2005, Venneri et al., 2007) 
This conclusion lends to an earlier study by Lu et al., on bone marrow derived 
vascular progenitors, which demonstrated blood vessel formation to be an angiogenic 
process (from pre-existing vessels) but also having a vasculogenic component. In 
other words, growth factors, cytokines and other key proangiogenic contributions 
derive not only from local tissues but also from bone marrow.(Lu et al., 2008) 
 
The identification of each subset thus allows further research into their respective 
physiological functions. Ziegler-Heitbrock et al. have shown that CD14+CD16+ 
monocytes have some features common with mature tissue macrophages.(Ziegler-
Heitbrock et al., 1993) However, animal-based studies on monocyte subsets are 
controversial due to substantial differences between human and murine monocyte 
subsets.(Qu et al., 2004, Auffray et al., 2009) Nahrendorf and colleagues compared 
monocytes in a model of mouse myocardial infarction and suggested that specific 
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signalling may depend on site and type of hypoxia/ischemia insult and time of 
recovery from this injury.(Nahrendorf et al., 2007) 
 
Although three monocyte subsets are now recognised, the majority of published 
studies only refer to two monocyte subpopulations (i.e., CD14+CD16- and 
CD14+CD16+ monocytes) without further subdivision of the CD16+ cells, and thus 
careful interpretation of such data is required. The CD16+ monocytes are infrequent 
(less than 15% in healthy humans), but their proportions are increased in patients with 
stenotic CAD, and myocardial infarction, being related to the up-regulation of 
inflammatory cytokines.(Schlitt et al., 2004, A.M Gotto Jr et al., 1990, Grage-
Griebenow et al., 2001) These data might indicate a possible role of CD16+ 
monocytes for the advanced inflammation-mediated arterogenesis/intraplaque 
angiogenesis. However, the relation of monocyte populations to systemic 
atherosclerosis (IMT, adventitial vasa vasorum) and high-risk indices for plaque 
destabilisation is clearly understudied.  Subset specificity may also be dependent on 
expression of multiple receptors and MCP-1-mediated signalling.(Capoccia et al., 
2008) Indeed, angiogenesis and monocyte subset involvement is a multiple stepwise 
process, which consists of two areas of recruitment, local and bone marrow, which are 
specific to the stimulating environment.(Capoccia et al., 2008) Further studies are 
being performed to delineate the specific functions of each of the monocyte subsets, 
but their specific roles in plaque progression, stability and rupture remains 
insufficiently understood at present.(Mehta NN, 2012) 
 
1.1.10. Plaque instability and rupture 
 
The volatile nature of an atheromatous plaque is responsible for approximately 60% 
of symptomatic carotid artery disease and about 75% of acute coronary events. (Burke 
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et al., 1997, Redgrave et al., 2006) Neovascularisation recently has been implicated as 
a possible contributor to the process by which an asymptomatic fibro-atheromatous 
plaque becomes a lesion vulnerable to rupture, although the precise mechanism of 
how this occurs remains unclear.(Kolodgie et al., 2003, Takaya et al., 2005, Milei et 
al., 1998) As the plaque progresses, the adventitial vasa vasorum is the site of 
initiation of intra-plaque vessels formation. (Kumamoto et al., 1995) Evidence has 
shown the presence of neo-vessels within the plaque has been associated to its 
rupture. (Kumamoto et al., 1995) In the comparison of stable plaques to those in both 
vulnerable and ruptured plaques, there is a 2 to 4 fold increase in the number of vasa 
vasorum, respectively. (Virmani, 2005) Although plaque deposits themselves may be 
localised and unique, the changes found in the arterial wall vascularisation are known 
to be systemically widespread, lending to the notion of atherosclerosis being a pan-
arterial disease.(Fleiner et al., 2004) However the factors which trigger the change, 
from a nonthreatening to unstable plaque remains poorly understood. The synthesis of 
pro-inflammatory molecules such as IL-6 and tumour necrosis factor-α, mediated by 
stimulation of TLR4 are upgraded by activated monocytes. (Satoh et al., 2006, 
Shantsila and Lip, 2009) The interaction between EPC and white blood cells results in 
an inflammatory cascade resulting from the interaction amongst CD14, a monocyte 
endotoxin receptor, acting together with a co-receptor, TLR leading to in monocytic 
activation. (Agema WR, 2004, Lauener RP, 1990) This monocyte activation 
subsequently enhances the affinity of monocyte ligands to adhesion molecules thus 
promoting monocyte–endothelium adhesion. (Lauener RP, 1990) Evidence for this 
has been demonstrated by the presence of micro-vessels within lipid-rich plaques 
strongly expressing adhesion molecules (ICAM-1, VCAM-1) thereby facilitating 
trans-endothelial migration of inflammatory cells (i.e. monocytes) into the plaque 
microenvironment. (O'Brien et al., 1996, van der Wal et al., 1992) This evidence 
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implicates the potential involvement of monocytes and there role in plaque 
neovascularisation and plaque rupture.  
 
1.1.11. Monocytes in Atherosclerosis Progression 
 
Uncontrolled lipid accumulation followed by rapid monocyte infiltration and 
phagocytosis of LDL mediated by scavenger receptors subsequently results in 
macrophage apoptosis. This understandably increases the atherosclerotic plaque core 
with ensuing necrotic tissue, collagen deposition and migration of smooth 
muscle.(Pamukcu et al., 2010) This pattern of monocyte/macrophage deposition and 
removal although protective by nature is only mediated by the inflammatory reaction 
it manifests itself. This unbalanced inflammation with excessive cytokine release 
from monocytes and enhanced monocyte expression of the TLRs promotes both 
angiogenesis and plaque growth and destabilisation.(Satta N, 1994, Dachary-Prigent 
J, 1993, Burnier L, 2009) Administration of statins to subjects with 
hypercholesterolaemia inhibited the expression of monocyte pro-inflammatory 
cytokines (TNF and IL1β) and the treatment has a well-documented capacity to 
reduce risk of unfavourable event in patients with stable coronary heart disease. 
(Ferro et al., 2000) Moreover, the long-term treatment with statins can prevent 
progression or even lead to regression of the atheroma, although the relative 
magnitude of lipid-independent pleiotropic effects of the statins in the overall benefits 
of the drugs remain unclear.(MAAS, 1994) 
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1.1.12. Adrenergic system and angiogenesis  
 
The adrenergic system have been shown to be implicated in regulation of expression 
of pro-angiogenic factors and angiogenesis.(Ristori C, 2011) For instance, high 
norepinephrine levels are linked to increased VEGF expression.(Guo K, 2009, Yang 
EV, 2009) Although the mechanisms of norepinephrine-mediated VEGF up 
regulation in atherosclerosis remain unclear, a post transcriptional mechanism has 
been revealed by which norepinephrine induced HIF α-1 production modulated VEGF 
expression in cancer cells.(Park SY, 2011) Interestingly this recent study draws 
attention to an older study that demonstrated norepinephrine’s effect on VEGF was 
mediated by a paracrine mechanism.(Weil J, 2003) 
 
In the absence of ischaemia or even exercise, the alpha adrenergic (α1A) system has 
been demonstrated to increase capillary blood flow via an increase in capillarity of 
skeletal muscles.(Dawson JM, 1989) In 2008, Ciccarelli demonstrated α1A to inhibit 
angiogenesis by interfering with EC proliferation and responsiveness to 
VEGF.(Ciccarelli M, 2008, Carmeliet P, 2000) Although expressed in many tissues, 
the primary role of beta-adrenergic system (β2A) receptors overall remains unclear. 
(Iaccarino G, 2005) In 2008, Leosco and colleagues demonstrated the promotion of 
angiogenesis with exercise resulting in improved β2A signalling. (Leosco D, 2008) 
This promotion of angiogenesis is also evidenced by the use of propranolol, a potent 
adrenergic blocking agent in the treatment haematopoietic malignancies whereby its 
anti-inflammatory and anti angiogenic properties have been demonstrated to reduce 
VEGF production and matrix metalloproteinase-2 (MMP-2) activity.(Hajighasemi F, 
2009) In the presence of ischaemia, Iaccarino et al., observed adrenergic down 
regulation of β2A with enhancement and preservation of capillaries along with the 
promotion of endothelial cell proliferation suggesting a vital role in regulation of 
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angiogenesis by the β2A system. (Iaccarino G, 2005) The augmentation of EC, shown 
to be demonstrated after a single episode of exercise, clearly has demonstrated a link 
between ischaemia and angiogenesis.(Rehman J, 2004) Most recently emphasis has 
been placed on identification of specific β2A receptor subtypes on lipopolysaccharide 
laden monocytes implicated in creation of the pro-inflammatory state, mediated by 
cytokine modulation and cyclic adenosine monophosphate (cAMP) dependent 
mechanisms.(Grisanti LA, 2010) Galasso et al. most recently, have shown a 
relationship between EPC cells and β2A receptors, going as far to demonstrate EPC’s 
ability to express β2A receptors, which in turn promotes EPC migration, and 
proliferation thereby augmenting angiogenesis. (Galasso G, 2013) 
 
1.1.13. Conclusion 
 
Atherosclerosis and its angiogenic component is an obvious feature of vascular 
disease. The regeneration of vascular beds with capillary sprouting relies on 
angiogenesis. Atherosclerosis has an inflammatory component, and MCP-1 plays a 
role in recruiting monocytes to the site of insult. Monocytes, important members of 
the innate immune system have been shown to play an intricate role in angiogenesis. 
Neovascularisation is a major contributor to plaque progression. Much more research 
is required to establish the exact mechanisms underlying the tightly regulated 
angiogenic processes. One approach would be to continue to investigate the potential 
presence of various subtypes of monocytes and their specific receptors and roles in 
cardiovascular disease. This hopefully would be useful for the development of new 
therapeutic targets for prevention of progression of atherosclerotic disease and its 
complications. 
 
 
 28
1.2. Carotid Ultrasound 
 
Stroke is the leading cause of adult disability and the second leading cause of death in 
both Europe and the United States. (Feigin, 2005) In the United Kingdom, it is 
estimated that the direct cost of stroke to the National Health Service is 2.8 billion 
pounds. (House of Commons, 2006) Leary et al. reported that in 1998 in the United 
States, 11 million people had experienced a neurovascular event at some point during 
their lifetime and, of those, only 770,000 were symptomatic. (Leary and Saver, 2003) 
They concluded that there were a substantial number of affected patients that were 
either unreported or even silently affected. It is estimated that 20-25% of strokes 
originate from the carotid artery and that carotid imaging should be part of any 
clinical stroke evaluation. (Weinberg, 2010, Gleason et al., 2001) 
 
Although angiography has remained the gold standard of imaging for any blood 
vessel, it tends only to be used when non-invasive methods require further 
clarification. (Weinberg, 2010) Carotid Doppler ultrasound (CUS) remains the 
primary method of detecting CD. (Wardlaw and Lewis, 2005) A number of clinical 
studies have shown that this non-invasive, inexpensive and reproducible modality, 
using various post-processing algorithms, can accurately measure percentage stenosis 
using peak systolic velocity.(Alexandrov et al., 1997) The North American 
Symptomatic Carotid Endarterectomy Trial (NACSET), and the European Carotid 
Surgery Trial (ECST), both differed on how to calculate the degree of CD. Both trials 
calculated the lumen diameter at the point of maximum of disease but NACSET 
divided this measurement by the distal ICA lumen (normal segment) whereas ECST 
used an estimated normal lumen diameter at the site of maximum disease. The 
NASCET method produced lower measurements of disease then that of ECST, 
significantly affecting overall outcomes lending to the continuing disagreement. 
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(Rothwell et al., 2003) For the purpose of this thesis, the ECST method was used, as it 
remains widely adopted by the UK. (Grant et al., 2003)  
 
NACSET, the Asymptomatic Carotid Artery Stenosis Trial (ACAST) and the 
Asymptomatic Carotid Surgery Trial (ACST), in particular, have all established 
guidelines for the use of CUS alone as the primary tool for determining the need for 
surgical intervention. (Barnett et al., 1998, Chambers and Donnan, 2005, Study et al., 
1995, Rothwell and Goldstein, 2004, Moneta et al., 1993) These large studies have 
shown benefit from surgical intervention (carotid endarterectomy, (CEA)) in patients 
with greater that 70% stenosis, but significant controversy surrounds the management 
of asymptomatic disease. (Barnett et al., 1998, Stansby et al., 2011) Nicolaides et al. 
specifically investigated the asymptomatic internal carotid artery stenosis and 
demonstrated a stroke risk of approximately 1% per year when the stenosis was 
greater than 70%.(Nicolaides et al., 2010) This is in direct contrast to symptomatic 
disease, which the NASCET trial showed the five-year stroke risk in patients with 60-
99% stenosis to be 16.2%, while in those with less then 60% the risk was reduced to 
8%. (Barnett et al., 1998) Most recently, Hirt investigated the progression of 
asymptomatic carotid disease with >50% stenosis and concluded that, over five years, 
the rapid progression of stenosis poses a significant stroke risk. (Hirt, 2011) In 
asymptomatic patients, the risk of stroke has been shown to be significantly increased 
in those with >90% CD, hence asymptomatic disease may not be benign, simply 
because most cerebrovascular events happen in patients who are not symptomatic. 
(Rothwell et al., 2004) These results continue to fuel scientific and clinical interest in 
the identification of plaque characteristics using imaging techniques, particularly 
CUS, to predict stroke risk, as well as to develop therapeutic strategies to prevent or 
inhibit disease progression.  
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Parasekevas et al. showed that the presence of carotid disease is a marker of 
widespread atherosclerotic disease. (Paraskevas et al., 2007) Pathological intimal 
media thickening (IMT) is recognised as the earliest atherosclerotic change and is 
primarily characterised by surface smooth muscle cells overlying relatively acellular 
lipid rich pools. (Kumamoto et al., 1995) IMT measurement remains objective, as 
IMT is not a defined morphological structure but an observation on ultrasound for 
which no clear anatomical structure is identified. (Coli et al., 2008) The body’s 
natural response to ischaemia is a repairing mechanism summarised by the term 
neovascularisation. This process is thought to originate in the adventitia. (Kumamoto 
et al., 1995) Histological studies have demonstrated that the development of an 
unstable plaque is related to plaque inflammation and neovascularisation. (Giannoni 
et al., 2009) The presence of plaque neovascularisation has been shown to be an acute 
predictor of unstable atherosclerotic lesions in cardiovascular and cerebrovascular 
patients. (Vicenzini et al., 2009) Understanding these processes of vessel adaptation 
or formation is fundamental to developing new therapeutic strategies or imaging 
techniques.   
 
Carotid contrast ultrasound (CEUS) imaging is an evolving technique, which focuses 
directly on the adventitial vasa vasorum (VV). These microvessels that supply 
vascular nutrition were first studied in the early 1980s in association with coronary 
disease, and have more recently been implicated in the progression of atherosclerotic 
plaques.(Barger et al., 1984, Magnoni et al., 2009) Atherosclerotic intraplaque 
neovascularisation is associated with high-risk plaque destabilisation. (Vicenzini et 
al., 2009) Under-nutrition and resulting ischemia of the growing atherosclerotic 
lesions triggers growth of new intra-wall/intra-plaque microvessels from adventitia, 
often being also associated with inflammatory processes. (Giannoni and Vicenzini, 
2009, Kumamoto et al., 1995) 
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The use of contrast microbubble agents in the delineation of carotid plaque 
vascularisation was first described by Feinstein. (Feinstein, 2006) Huang et al. 
demonstrated a clear correlation with contrast ultrasound and plaque morphology. 
(Huang et al., 2007) Since then, a number of studies have further enhanced the 
rationale for improving the technique but, to the knowledge of the authors, an 
agreeable validated methodology has not been developed to date. These studies are all 
limited by their varying methods of dosage/rate of contrast, equipment used, and 
assessment of neovascularisation.  
 
Quantification of plaque neovascularisation may improve identification of high risk 
lesions limited clinical tools are currently available. Ultrasound contrast agents 
remain within the vascular space, and therefore can be detected by their reflective 
resonation to highlight the presence of vascular disease.(Clevert et al., 2011) More 
recently, carotid contrast imaging, an evolving technique, has been used to focus on 
the plaque and adventitial vasa vasorum.(Clevert et al., 2011) However, 
reproducibility of the method is poorly established.(Hoogi et al., 2011, Papaioannou 
et al., 2009, Coli et al., 2008, Huang et al., 2007, Giannoni et al., 2009, Magnoni et 
al., 2009) 
Therefore, one of the aims of my thesis was to develop a method for the accurate and 
agreeable detection of carotid plaque vasculature using CEUS.  
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Table 5: Comparison of carotid contrast studies. 
Study n U/S machine Probe Contrast 
Agent 
Injection 
of 
contrast 
Time to 
scan 
Duration 
of Scan 
♯ of 
reviewers
Variability Assessment of neovascularisation 
(Shah et al., 
2007)  
17 GE Vivid 7  
& ATL HDI 
5000 
GE: 
7L 
ATL: 
7-4 L 
 
Optison Bolus 
0.5-1.0ml 
+ Saline 
2-3ml 
15-
30sec 
NS 3 
 
NS o= no neovascularisation within 
plaque 
1= limited appearance of 
neovascularisation within plaque 
2= moderate neovascularisation 
within plaque 
3= pulsating, arterial vessel within 
plaque 
(Papaioannou 
et al., 2009) 
1 GE Vivid 7 10L Sonovue Bolus  
2.5cc + 
2.5cc 
Saline 
during 
injection
90sec NS NS ROI enhancement 
(Coli et al., 
2008) 
32 GE Vivid 7  7L Optison Bolus 
2ml + 
repeat 
(dilution 
3ml 
contrast 
+ 7ml 
Saline) 
Max 2 
bolus 
NS 2 min 
after 
each 
bolus 
 
2 NS 1= no bubbles within plaque or 
bubbles confined to plaque 
adventitial side 
2= bubbles reaching plaque core 
and/or extensive contrast agent 
enhancement throughout plaque 
(Huang et al., 
2007) 
63 Acuson 
Sequoia 512 
scanner 
15L  Sonovue 2.4ml 
bolus 
Over 3 
NS NS NS NS Time intensity curve analysis 
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n, number of patients; U/S, ultrasound; Probe, MHZ-Linear Array; NS, not stated; ♯, number. 
(Siemens) sec 
(Giannoni et 
al., 2009) 
77 Acuson 
Sequoiq 512 
(Siemens) 
15L  Sonovue 2.5ml 
bolus 
followed 
by two 
other 
1.25 
bolus 
each 
followed 
by Saline 
NS NS NS NS type 1= rare, discrete contrast 
enhancement with microvessels 
large diameter 5-60μm 
type II – diffuse contrast 
enhancement, with microvessels of 
small diameter, 20-30 m, with 
VEGF staining. 
(Vicenzini et 
al., 2007) 
23 Acuson 
Sequoiq 512 
(Siemens) 
15L 
 
Sonovue Bolus 
2.5ml + 
10ml 
saline 
flush 
NS NS NS NS Observation only 
(Magnoni et 
al., 2009) 
25 GE Vivid 7 7L  Optison Bolus 
2ml + 
repeated  
Max=6ml
30 
seconds 
2 min 2 95% limits 
of the 
agreements 
varied 
between 
.131 and 
0.134 
Blood flow imaging modality with 
background subtraction 
(periadventitial study) 
 CHAPTER II. METHODS 
 
2.1. Patient selection 
 
I recruited 160 patients divided into 4 groups: (i) 40 patients with carotid disease 
(CD) ≥50% and documented CAD (grp.1 CD. >50), (ii) 40 patients with carotid 
disease <50% and documented CAD (grp.2 CD<50), (iii) 40 asymptomatic control 
subjects with hypercholesterolaemia (grp.3 HC) and (iv) 40 asymptomatic control 
subjects without hypercholesterolaemia (grp.4 NC). The number of patients recruited 
was calculated based on my hypothesis that my primary cellular marker, 
CD14low/CD16+ monocytes, will be raised by 0.3 standard deviation (i.e. from 50 
cells/μl in controls to 55.9 cells/μl in patients with CAD without carotid stenosis and 
further to 61.8 cells/μl in CAD patients with carotid stenosis ≥50%.  
 
The participants were recruited from Sandwell and West Birmingham Hospital NHS 
Trust during the period May 2010 and May 2011. My study was approved by the 
local research ethics committee and all participants gave written informed consent.   
 
I assessed CD and intraplaque neovascularisation using CEUS (see below). I 
confirmed the presence of stable CAD by history and/or previous elective coronary 
angiography, with no acute hospital admission for ≥3 months. Grp.3 HCs were 
recruited from our outpatient lipid clinic and had total cholesterol level above 5.0 
mmol/L but without clinical evidence of symptomatic arthrosclerosis. I identified and 
recruited grp. 4 NC from hospital staff, relatives of patients, and local general 
practices and were healthy with no clinical evidence of symptomatic arthrosclerosis 
and cholesterol levels below 5.0 mmol/L. I excluded from all groups any patient with 
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the following criteria; any neoplastic, inflammatory diseases, and significant kidney 
disease.  
 
All subjects were invited to attend our research clinic in the morning, after abstaining 
from smoking from midnight of the preceding day. Following a 20-minute supine 
rest, a 20ml blood sample was taken for flow cytometric studies and ELISA (below) 
and carotid ultrasound imaging was performed (below). 
 
2.2. Flow cytometry 
 
I performed flow cytometric analysis using the BD FACS Calibur flow cytometer 
(Becton Dickinson, Oxford, UK [BD]) as published previously by my 
supervisor.(Shantsila et al., 2011) The technique is robust and highly reproducible. 
 
2.2.1. Absolute count of monocyte subsets  
 
Mouse anti-human monoclonal fluorochrome-conjugated antibodies anti-CD16-Alexa 
Fluor 488 (clone DJ130c, AbD Serotec, Oxford, UK), anti-CD14-PE (clone MфP9, 
BD), anti-CD42a-PerCP (clone Beb1, BD) and anti-CCR2-APC (clone 48607, R&D) 
were mixed with 50μl of fresh EDTA anticoagulated whole blood in BD TruCount 
tubes (BD) containing a strictly defined number of fluorescent count beads.(Shantsila 
et al., 2011, Shantsila et al., 2012, Tapp et al., 2012, Wrigley et al., 2013) After 
incubation for 15 minutes red blood cells were lysed by 450μl of BD lysing solution® 
(BD) for 15 minutes followed by dilution in 1.5 ml of PBS and immediate flow 
cytometric analysis. Monocytes were selected by gating strategies based on forward 
and side-scatter properties to select monocytes, side scatter properties versus CD14 
expression to exclude granulocytes, and un-gated CD14 versus CD16 expression to 
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exclude natural killer lymphocytes. Monocyte subsets were defined as Mon1, Mon2, 
and Mon3. Monocyte platelet aggregates (MPAs) were defined as events positive to 
both monocyte markers (as above) and the platelet marker CD42a (glycoprotein IX). 
Absolute counts of monocyte subsets (cells/μl) were calculated count beads according 
to the manufacturer recommendations.  
 
2.2.2. Expression of surface antigens on monocyte subsets  
 
For my analysis of surface antigens, 100μl of whole blood was incubated with mouse 
anti-human monoclonal fluorochrome-conjugated antibodies for 15 minutes in the 
dark. Red blood cells were lysed with 2ml of BD lysing solution® for 10 min, washed 
in phosphate buffered saline followed by immediate flow cytometric analysis. Anti-
CD16-Alexa Fluor 488 (clone DJ130c, AbD Serotec, Oxford, UK) and anti-CD14-
PerCP-Cy5.5 (clone M5E2, BD) were used for definition of monocyte subsets into 
Mon1, Mon2, and Mon3. PE-conjugated antibodies were used against TLR4 (clone 
285219, R&D), CXCR4 (clone 12G5, R&D). APC-conjugated antibodies were used 
against IL6 receptor (clone 17506, R&D), integrin α4/CD49d, VCAM-1 (clone 7.2R, 
R&D), VEGF (clone 89106, R&D), Tie2 (clone 83715, R&D).  
 
Table 6:Variability 
Flow Cytometry:    
 Protocol Validation Monocytes 4.6% 
 Inflammatory markers: ILR6 5.6% 
 Angiogenic markers: VEGFR 5.7% 
 Angiogenic markers: TIE2 2.3% 
ILR6, interleukin-6 receptor, VEGFR, vascular endothelial growth factor receptor, TIE2, tyrosine 
kinase receptor 
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2.3. Carotid Ultrasound 
 
I used a Philips Compact Xtreme CX50 (Bothel, WA, USA) portable ultrasound 
system with an L12-3 (3-12 MHz frequency) probe was for imaging of the carotid 
arteries. All images I captured digitally were transferred to a Philips multi-modality 
image management system, Xcelera with QLAB 7.1 software for analysis and 
assessment. Each patient underwent CUS followed by contrast in a single session. 
Images were acquired with the participant’s head rotated 45° away from the side of 
study. A magnified, grey-scale B-mode images of the carotid artery were obtained 
bilaterally at 3 levels: distal common carotid artery (CCA), carotid bifurcation and the 
proximal internal carotid artery (ICA) in three different longitudinal planes (anterior 
oblique, lateral and posterior oblique) and also in the transverse projection. (Grant et 
al., 2003) I captured a single static image for the CCA, and 2 images, each at different 
angles, were captured for the carotid bifurcation and the ICA. All still images were 
captured at end-diastole. A 2 to 4 sec real-time cine video of the CCA and carotid 
bifurcation was recorded, capturing at least 3 complete cardiac cycles. 
IMT and the degree of CD (≥ 50% or less 50%) were determined according to the 
current guidelines. (Wardlaw and Lewis, 2005) The inter- and intra- observer 
coefficient of variation in our laboratory was <5%. 
 
2.4. Contrast carotid ultrasound 
 
The Philips CX50 carotid contrast ultrasound pre-sets I used were as follows: 
frequency:  26Hz, dynamic range: 66, Edge 3, Map G, Ave. 2, Depth 3 cm. 
I performed CEUS using Sonovue (Bracco, Milan, Italy) echo contrast determined 
from my previously published validated protocol. (Jaipersad AS, 2013a)  
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Figure 5: Algorithm used for carotid contrast ultrasound.                                 
CCA, common carotid artery, ICA, internal carotid artery, ECA, external carotid artery
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In my protocol, SonoVue (Bracco Imaging S.p.A., Milan, Italy) contrast agent 
(sulpher hexafluoride microbubbles) was injected using a Vuejet (BR-INF100) 
infusion pump (Bracco Imaging S.p.A., Milan, Italy). SonoVue has a half-life of 6 
min and is cleared by the respiratory system.(Clevert et al., 2011) Documented overall 
reporting rate of serious adverse effects like sensory motor paresis or chest pain with 
ST-segment elevation on ECG are less than 0.01%.(Piscaglia and Bolondi, 2006) An 
infusion pump was used to achieve standardized results, by improving image quality 
and minimization of artifacts.(Boyajian R.A., 2000, Albrecht et al., 1998) The 
contrast was infused via an antecubital vein (20 Gauge Venflon) with rate of 1.3 ml/s 
with 6 ml of SonoVue typically used.  
 
A linear array probe, with a mechanical index 0.08-0.10, was used to achieve the best 
possible visualization of plaque morphology and vascularization, starting 30 sec after 
beginning the infusion. During the contrast-enhanced ultrasound imaging I gave 
special attention to the previously identified lesions. All patients tolerated the exam 
well with no side effects. High quality images were available for all patients. After 30 
min the patients were deemed fit to go home. 
 
Neovascularisation was measured by 2 independent observers of which one was 
myself, to test inter-observer variability, and repeated by myself to test intra-observer 
variability on 3 separate occasions (initial review, at week 2, and at 3 months). Plaque 
neovascularisation was categorised as follows: Grade 0 - no contrast within the 
plaque; Grade 1 - bubbles confined to the plaque adventitial side; or Grade 2 - bubbles 
reaching the plaque core and/or contrast agent enhancement throughout the plaque.  
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Figure 6. Contrast-enhanced Carotid Ultrasound. 
A: Carotid bifurcation with contrast agent. B: Grade 0 ICA lesion (no contrast within the plaque); C: 
Grade 1 ICA lesion (bubbles confined to the plaque adventitial side); D: Grade 2 ICA lesion (bubbles 
reaching the plaque core and/or contrast agent enhancement throughout the plaque). CAR BIF, carotid 
bifurcation, ECA, external carotid artery, ICA, internal carotid artery  
 
The inter- and intra- observer coefficient of variation in our laboratory was <5%. 
(Jaipersad AS, 2013a) 
 
2.5. Enzyme-linked immunosorbent assay (ELISAs) 
 
Following centrifugation of peripheral venous blood the plasma samples I obtained 
were stored at –70oC for batched analysis.  I measured Tie 2, angiopoietin and VEGF 
 
B A 
C D 
ECA 
CAR 
BIF 
ICA 
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in citrated plasma by commercial ELISAs technique (R&D Systems, Abingdon, UK). 
Intra- and inter-assay coefficients of variation were <5% and <10% respectively. My 
lower limits of detection for Tie2 and angiopoietin were 0.16 ng/mL and 31.2 pg/ml 
for VEGF. 
 
2.6. Power calculation 
 
Based on my units previous work (Shantsila et al., 2011), the calculated minimum 
number of participants required to achieve 80% power to detect a difference of 0.5 
standard deviations in mean monocyte count between the study groups was n=35 for 
the cross-sectional study 
 
2.7. Statistical analysis 
 
I expressed normal data as mean [standard deviation, SD], and non-normal data as 
median [interquartile range, IQR]. The between group comparisons were done using 
ANOVA with Tukey’s post-hoc test (normal data) or Kruskal-Wallis text with Dunn’s 
post-hoc test (non-normal data). The predictive value of the study parameters for CD 
(assessed as maximal stenosis percentage detected from both sides), and from IMT 
(assessed as average IMT from the right and left sides), were established using linear 
regression analysis. My analyses were done across the whole study population 
(n=160).  
 
Predictive value for intraplaque neovascularisation were done using multinomial 
regression analysis among participants with detectable atherosclerotic plaques and 
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good quality contrast study (n=128). The choice of variables for multivariate 
regression analyses was based on their significance on univariate analysis and 
relevance. Two-tailed p values were used. Correlation analyses were performed using 
Spearman test. The differences/effects were considered significant with p value less 
0.05, except for comparisons of surface monocyte markers where p value less 0.01 
was considered significant to account for multiple comparisons. 
In chapter 5, my values of the study parameters before and after the statin withdrawal 
were compared using paired T-test (normal data) or Wilcoxon text (non-normal data). 
Correlation analysis was done using Pearson test (normal data) or Spearman test (non-
normal data). I hypothesized an intervention effect of 4 units (standard deviation 10 
units) in a test statistic with a normal distribution. To achieve this at 2p<0.05 and 1-
beta = 0.8, 52 paired samples are required. Therefore for additional confidence in 
view of multiple analyses, I recruited in excess of this number.  
I performed statistical analysis with SPSS version20 software (IBM) and produced 
graphs with GraphPad Prism 4.0 software (La Jolla, CA, USA), and calculated the 
power calculation on Minitab 16 (Minitab Inc., Philadelphia, USA). 
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CHAPTER III. EVALUATION OF CAROTID PLAQUE 
NEOVASCULARISATION USING CONTRAST ULTRASOUND 
 
3.1. Abstract  
 
CEUS is increasingly used to improve visualisation of carotid arteries. However, its 
reproducibility and utility for clinical research are not well established. The aim of the 
present study was to assess agreeability of detection of carotid artery wall 
neovascularisation using CEUS. Complete sequenced CEUS images from 10 
individuals were analysed for the presence of carotid arterial wall neovascularisation. 
The images were acquired using Philips CompactXtreme CX50 ultrasound unit with 
an L12-3 probe and Bracco SonoVue contrast agent. The carotid wall 
neovascularisation was graded by 2 independent observers with inter-/intra-observer 
agreement (κ) calculated. Inter-observer κ values for intraplaque neovascularisation 
(mean [95% confidence interval]) was 0.67 [0.40-0.94] for the left side. Intra-observer 
κ values for intraplaque neovascularisation was 0.65 [0.38-0.92]. No study-related 
complications were observed. The CEUS method although semi-quantitative shows 
moderate-to-strong intra- and inter-agreement for the results and can be used for 
clinical research purpose.   
 
3.2. Aim 
 
Atherosclerotic intraplaque neovascularisation is associated with high-risk plaque 
destabilisation. (Vicenzini et al., 2009) Under-nutrition and resulting ischemia of the 
growing atherosclerotic lesions triggers growth of new intra-wall/intra-plaque 
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microvessels from adventitia, often being also associated with inflammatory 
processes. (Giannoni and Vicenzini, 2009, Kumamoto et al., 1995) 
 
Quantification of plaque neovascularisation may improve identification of high risk 
lesions limited clinical tools are currently available. Ultrasound contrast agents 
remain within the vascular space, and therefore can be detected by their reflective 
resonation to highlight the presence of vascular disease.(Clevert et al., 2011) More 
recently, carotid contrast imaging, an evolving technique, has been used to focus on 
the plaque and adventitial vasa vasorum.(Clevert et al., 2011) However, 
reproducibility of the method is poorly established.(Hoogi et al., 2011, Papaioannou 
et al., 2009, Coli et al., 2008, Huang et al., 2007, Giannoni et al., 2009, Magnoni et 
al., 2009) The aim of this chapter of my thesis was to evaluate agreeability of 
detection of carotid plaque vasculature using carotid contrast ultrasound.  
 
3.3. Methods 
 
I performed this validation study on 10 complete sequenced ultrasound images 
selected randomly from a larger pool of 160 patients by myself, and I individually 
analysed each for the presence of carotid arterial wall neovascularisation. 
Neovascularisation was assessed by 2 observers of which one was myself and another 
independent operator, to test inter-observer variability, and repeated by myself to 
establish the test intra-observer variability on 3 separate occasions (initial review, at 
week 2, and at 3 months). The patients personal details were removed from the scans 
to avoid possible bias during their assessment.   
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CEUS was performed as discussed in the main methodology section.  
 
I calculated using SPSS version 20 (IBM) the agreement between the 2 reviewers or 
between different time-points (kappa, κ). (Cohen, 1968) Landis and Koch graded κ 
values as follows: κ <0 - no conformity; κ = 0-0.20 - slight agreement; κ = 0.2-0.40 - 
fair agreement; κ = 0.41-0.60 - moderate agreement; κ = 0.61-0.80 - substantial 
agreement; and κ = 0.81-1 - almost perfect agreement. (Landis and Koch, 1977) 
 
3.4. Results 
 
Ten patients were studied (mean [standard deviation] age 66 [13] years, 50% male). 
Six patients had history of hypertension, 7 had stable coronary artery disease, 3 were 
current smokers, and 9 received statins. Two patients had no CD, 4 had unilateral CD, 
and 2 subjects had >50% CD. Inter-observer κ values for intraplaque 
neovascularisation (mean [95% CI]) was 0.67 [0.40-0.94] for the left side. Intra-
observer κ values for intraplaque neovascularisation (mean [95% CI]) was 0.65 [0.38-
0.92] for measurements taken from both (i.e. right and left) sides.  
 
3.5. Discussion 
 
There is a growing awareness that a number of molecular processes such as 
inflammation, lipid accumulation, angiogenesis and thrombosis may occur at sites of 
plaque development and that these molecular processes are highly related to the 
physiological progression to rupture. (Nighoghossian et al., 2005) Although the 
precise method of remodeling of an asymptomatic plaque into a vulnerable plaque 
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remains unclear, neovascularisation has been implicated as an important contributor 
to plaque rupture. (Kolodgie et al., 2003, Takaya et al., 2005) Compared with stable 
patients, those with vulnerable coronary plaques had a 2-fold increase in their vasa 
vasorum density increasing further to 4-fold in ruptured plaques. (Virmani, 2005) 
These changes in the arterial wall are not specific to any particular arterial bed but 
occur throughout the arterial vasculature, reflecting a systemic nature atherosclerosis. 
(Fleiner et al., 2004, Nazemi et al., 1990, Wakhloo et al., 2004)  
 
In the current study, I was able to demonstrate, using a standardised technique with 
the use of SonoVue contrast agent, the presence of contrast agent within the 
atherosclerotic plaque. The study results confirm the potential of contrast-enhanced 
carotid ultrasonography for assessment of intra-plaque neovascularisation. (Xiong et 
al., 2009) The inter- and intra-observer variability for detecting the presence of carotid 
plaque neovascularisation can be acceptable for research purposes. Clinical utility of 
the approach needs to be assessed in prospective studies.  
 
3.6. Conclusion 
 
The application of this method can potentially be adapted, following further analysis, 
for the development of quantitative measurements; this application is currently under 
review. The clinical implications of carotid contrast ultrasound may be at the forefront 
of further enhancing plaque knowledge, predicting stroke risk and helping to develop 
targeted therapeutic strategies on plaque remodeling and stabilisation. The method I 
propose here for detecting neovascularisation is novel and accurate and although it 
remains a subjective method, my study has demonstrated that it is agreeable. 
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CHAPTER IV. EXPRESSION OF MONOCYTE SUBSETS AND 
ANGIOGENIC MARKERS IN RELATION TO CAROTID PLAQUE 
NEOVASCULARISATION IN PATIENTS WITH PRE-EXISTING 
CORONARY ARTERY DISEASE AND CAROTID DISEASE 
 
4.1. Abstract 
 
Aim: To characterise blood monocyte subsets in patients with different degrees of 
carotid atherosclerosis and pathological carotid plaque neovascularisation.  
Methods: Assessment of carotid plaque neovascularisation using contrast 
ultrasonography and flow cytometric quantification of monocyte subsets and their 
receptors involved in inflammation, angiogenesis and tissue repair was done in 40 
patients with carotid disease (CD) ≥50% and documented CAD (grp.1 CD>50), 40 
patients with CD <50% and documented CAD (grp.2 CD<50), 40 
hypercholesterolaemic controls (grp.3 HC group) and 40 normocholesterolaemic 
controls (grp.4 NC). 
Results: Grp.1 CD>50 and grp.2 CD<50 groups had increased counts of Mon1 
(“Classical” CD14++CD16-CCR2+ cells) compared to grp.3 HCs (p=0.03, and 
p=0.009). Mon3 (CD14+CD16++CCR2- cells) were only increased in grp.2 CD<50 
compared with grp.3 HCs (p<0.01). Both grp.1 CD>50 and grp.2 CD<50 groups 
showed increased expression of proinflammatory interleukin-6 receptor on Mon1 and 
Mon2 (CD14++CD16+CCR2+ cells); TLR4, proangiogenic Tie2 on all subsets 
(p<0.01 for all). In multivariate regression analysis only high Mon1 count was a 
significant predictor of carotid disease (p=0.04) and intima-media thickness (p=0.02). 
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In multivariate regression analysis only Mon1 subset was significantly associated 
with severe, Grade 2 neovascularisation (p=0.034). 
Conclusion: Classical monocytes (Mon1) represent the only monocyte subset 
predictive of the severity of carotid and systemic atherosclerosis, such as carotid IMT, 
degree carotid disease and presence of carotid intraplaque neovascularisation.  
 
4.2. Introduction 
 
The changes in arterial wall vascularisation are uniformly present in different arterial 
beds (in contrast to often selected location of the plaques themselves) and support the 
concept of symptomatic atherosclerosis as a panarterial disease.(Fleiner et al., 2004) 
However, the factors/ mechanisms triggering the switch from relatively benign 
systemic atherosclerosis (i.e. intima-media thickening, increased density of adventitial 
vasa vasorum) to rapidly progressive stenotic or associated with intraplaque 
neovascularisation are poorly understood. 
 
A potential link between monocytes and abnormal plaque angiogenesis has a strong 
biological justification. Monocytes activity is directly associated with the 
inflammatory status. Activated monocytes promote the synthesis of proinflammatory 
molecules, such as interleukin-6 (IL-6) and tumour necrosis factor-α, mediated by 
stimulation of Toll-like receptors (TLR4).(Satoh et al., 2006, Shantsila and Lip, 2009) 
Monocyte activation enhances the affinity of monocyte ligands to adhesion 
molecules, thus promoting monocyte–endothelium adhesion.(Lauener et al., 1990) In 
support of this argument, microvessels within lipid-rich plaques strongly express 
adhesion molecules, such as vascular cell adhesion molecule (VCAM), with 
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monocytes expressing receptors to the molecule.(O'Brien et al., 1996, van der Wal 
AC, 1992) Their interaction may facilitate transendothelial migration of inflammatory 
cells (i.e. monocytes) into the plaque microenvironment. Also, monocytes per se have 
proangiogenic properties.(Jaipersad AS, 2014) Additionally, monocytes have been 
found to constitute the dominant population among circulating cells expressing type2 
receptor for vascular endothelial growth factor (VEGF), Tie2, CXCR4 – which are 
receptors implicated in angiogenesis and tissue remodelling.(Romagnani et al., 2005) 
Whilst a role for macrophages in the development and progression of atherosclerosis 
has long been recognised, the role of their blood-borne ancestors – monocytes, 
represented by different functional subsets – has scarcely been addressed.(Schmitz 
and Grandl, 2008) 
 
In my study I firstly aimed to assess different monocyte subsets and their expression 
of receptors involved in inflammation, angiogenesis/tissue remodelling in patients 
with different degrees of carotid atherosclerosis with evidence of a systemic 
atherosclerotic process (i.e., concomitant coronary artery disease (CAD)), who were 
compared to hypercholesterolaemic and normocholesterolaemic controls. Second, I 
aimed to establish a relation between the monocyte subsets and carotid plaque 
neovascularisation, by using a novel method of contrast carotid ultrasonography as 
previously published by our unit. (Jaipersad AS, 2013a)  
 
4.3. Methods 
 
I performed both flow cytometry and CUS as discussed in the main methodology 
section.  
50 
4.4. Results 
 
4.4.1. Monocyte subsets and carotid atherosclerosis 
 
The study groups were matched for age and gender, but, as expected, there were 
significant differences between the groups in clinical characteristics. 
 
Table 7. Demographic, clinical and carotid artery characteristics in the study 
groups 
 Grp. 1 
CD>50 
(n=40) 
Grp.2 
CD<50 
(n=40) 
Grp. 3 
HC 
(n=40) 
Grp. 4 
NC 
(n=40) 
p value
Age, years 70 [9] 69 [9] 67 [7] 67 [6] 0.22 
Gender (male), n [%] 24 [60] 27 [68] 17 [43] 17 [43] 0.053 
Systolic BP, mmHg 139 [20] 137 [21] 148 [19] 143 [23] 0.08 
BMI, kg/m2 26 [5] 28 [7] 29 [6] 27 [5] 0.12 
Cholesterol, mmol/L 4.0 [0.6]†‡ 3.9 [0.6]†‡ 6.7 [1.1]‡ 3.3 [0.9] <0.001 
eGFR, mL/min/1.67 71 [9] 74 [11] 72 [10] 73 [10] 0.59 
Hypertension, n [%] 28 [70]†‡ 23 [58]‡ 17 [43]‡ 0 <0.001 
Diabetes, n [%] 10 [25]†‡ 7 [18]†‡ 1 [3] 0 0.001 
Current smokers, n [%] 16 [40]†‡ 12 [30]‡ 6 [15] 7 [18] 0.022 
Aspirin, n [%] 37 [93]†‡ 36 [90]†‡ 6 [15]‡ 0 <0.001 
ACEI/ARB, n [%] 23 [58]†‡ 17 [43]†‡ 4 [10]‡ 0 <0.001 
CCB, n [%] 20 [50]†‡ 9 [23]‡ 10 [25]‡ 0 <0.001 
Beta-blocker, n [%] 15 [38]*†‡ 21 [53]†‡ 4 [10]‡ 0 <0.001 
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Statin, n [%] 40 [100]†‡ 40 [100]†‡ 0 0 <0.001 
Intima-media thickness 
Right CCA, mm 0.75 [0.2] 0.74 [0.1] 0.68 [0.1] 0.70 [0.1] 0.07 
Left CCA, mm 0.78 [0.2] 0.81 [0.2] 0.74 [0.1] 0.76 [0.1] 0.15 
Carotid Disease 
Right CCA, n [%] 
 <20% 
 
6 [15] 
 
13 [33] 
 
32 [80] 
 
31 [78] 
 
<0.001 
20-49% 8 [20] 27 [68] 8 [20] 9 [23]  
>50% 26 [65] 10 [25] 0 0  
Left CCA, n [%] 
 <20% 
 
7 [18] 
 
7 [18] 
 
25 [63] 
 
30 [75] 
 
<0.001 
20-49% 4 [10] 33 [83] 15 [38] 10 [25]  
>50% 29 [73] 0 0 0  
Plaque neovascularisation 
Right CCA, n [%] 
Grade 1 
 
17 [43] 
 
14 [35] 
 
2 [5] 
 
2 [5] 
 
<0.001 
Grade 2 4 [10] 4 [10] 5 [13] 1 [3]  
Left CCA, n [%] 
Grade 1 
 
11 [28] 
 
13 [33] 
 
9 [23] 
 
7 [18] 
 
0.005 
Grade 2 7 [18] 4 [10] 8 [20] 3 [8]  
*p<0.05 vs. grp2. CD<50 group, †p<0.05 vs.  grp.3 HCs, ‡p<0.05 vs. grp.4 NCs. Continuous data are 
presented as mean [standard deviation] for normal data or median [interquartile range] for non-normal 
data. ACEI/ARB, angiotensin converting enzyme inhibitor/angiotensin receptor blocker; BMI, body 
mass index; BP, blood pressure; CCA, common carotid artery; CCB, calcium channel blocker; CD>50, 
carotid disease ≥50 and CAD; CD>50, carotid disease <50 and CAD; eGFR, estimated glomerular 
filtration rate; HC, hypercholesterolaemic controls; NC, normocholesterolaemic controls. 
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 A proportion of control subjects had non-significant asymptomatic carotid 
atherosclerotic lesions (i.e., <50%) reflecting the natural pattern of high prevalence of 
subclinical stable atherosclerotic plaques in older populations. The grp.1 CD>50 and 
grp.2 CD<50 groups were well matched for majority of demographic and clinical 
characteristics. There was no significant difference in IMT between the study groups. 
All patients from grp.1 CD>50 and grp. 2 CD<50 groups received statins, whilst 
control groups were free of statins. 
 
Grp. 1 CD>50 group had increased counts of Mon1 compared to grp.3 HCs (p=0.03) 
and MPAs lower than in grp.2 CD<50 group (p<0.001). This group also had increased 
expression of CD14 on Mon2 (p=0.001 vs. grp.3 HC); IL6R on Mon1 and Mon2 
(p<0.001 vs. grp.4 NC); TLR4 on Mon1 and Mon3 vs. grp.2 CD<50 (p<0.01) and 
TLR4 on all subsets vs. grp.3 HC and grp.4 NC (p<0.001); VEGF receptor 2 on 
Mon2 (p<0.001 vs.grp.4 NC) and on Mon3 (p<0.01 vs. grp.3 HC and p<0.001 vs. 
grp.4 NC); CXCR4 on all subsets (p<0.001 vs. grp.4 NC for all 3 subsets); Tie2 on 
Mon1 (p<0.001 vs. grp.4 NC and grp.3 HC), Mon2 (p<0.001 vs. grp.4 NC), and 
Mon3 (p<0.01 vs. grp.4 NC). Grp.1 CD>50 group had decreased CD16 expression on 
all subsets (p≤0.001 vs. all other groups). 
 
Similarly to grp.1 CD>50, grp.2 CD<50 group had increased counts of Mon1 
compared to grp.3 HCs (p=0.009). 
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Table 8. Monocyte subsets in the study groups 
 Grp.1 
CS>50 
(n=40) 
Grp.2 
CS<50 
(n=40) 
Grp.3 
HC 
(n=40) 
Grp.4 
NC 
(n=40) 
p value
Counts of monocyte subsets and MPAs 
Mon1, per µL 472 [153]‡ 484 [148]‡ 420 [121] 385 [130] 0.005 
Mon2, per µL 36 [27-67] 35 [27-58] 32 [20-60] 25 [18-50] 0.13 
Mon3, per µL 56 [42-78] 62 [46-77]‡ 49 [38-73] 44 [34-54] 0.008 
MPA, per µL 79 [60-104]* 142 [91-162]‡ 93 [77-129]‡ 61 [39-100] <0.001
Monocyte surface markers 
CCR2 (Mon1) 157 [46] 160 [32] 154 [31] 141 [38] 0.093 
CCR2 (Mon2) 130 [42] 116 [22] 117 [25] 112 [26] 0.049 
CCR2 (Mon3) 15 [2] 16 [2]‡ 15 [1] 15 [3] 0.002 
CD14 (Mon1) 1351 [286] 1373 [248] 1291 [336] 1434 [308] 0.192 
CD14 (Mon2) 1435 [361]† 1349 [327] 1129 [312] 1308 [388] 0.001 
CD14 (Mon3) 154 [53] 160 [34] 150 [39] 163 [45] 0.52 
CD16 (Mon1) 8.4 [2.1]*†‡ 11.5 [1.8] 11.7 [1.8] 12.3 [2.1] <0.001
CD16 (Mon2) 45 [12]*†‡ 66 [11] 67 [8] 66 [10] <0.001
CD16 (Mon3) 123 [50]*†‡ 175 [59] 187 [57] 182 [64] <0.001
IL6R (Mon1) 75 [15]‡ 78 [15]‡ 67 [23]‡ 53 [22] <0.001
IL6R (Mon2) 66 [12]‡ 69 [12]‡ 59 [20]‡ 44 [21] <0.001
IL6R (Mon3) 34 [8] 40 [11] 42 [13] 34 [13] 0.003 
TLR4 (Mon1) 5.7 [4.5-7.1] *†‡ 3.7 [2.4-4.7]† 1.6 [1.5-1.8] 1.7 [1.5-4.7] <0.001
TLR4 (Mon2) 8.7 [5.9-14]†‡ 5.3 [2.4-8.7]†‡ 1.3 [1.3-1.5] 1.3 [1.2-6.7] <0.001
TLR4 (Mon3) 3.4 [2.6-4.1]*†‡ 1.9 [1.5-2.9]‡ 1.3 [1.2-1.4] 1.2 [1.1-2.4] <0.001
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CD49d (Mon1) 10 [7.7-13]* 17 [12-22]†‡ 11 [5.4-18]‡ 2.9 [2.3-10] <0.001
CD49d (Mon2) 18 [14-23]* 37 [25-44]†‡ 26 [8.6-33] 6.5 [3.6-21] <0.001
CD49d (Mon3) 28 [26-37]* 53 [32-69]‡ 36 [19-49] 25 [15-31] <0.001
VEGF receptor 2 (Mon1) 6.6 [5.4-8.1] 6.0 [4.9-7.1] 5.8 [4.7-7.0] 5.4 [4.0-7.9] 0.087 
VEGF receptor 2 (Mon2) 12 [10-18]‡ 10 [8.3-14] 10 [6.9-13] 8.4 [5.6-12] 0.001 
VEGF receptor 2 (Mon3) 3.7 [2.8-4.8]†‡ 2.9 [2.2-3.5]† 2.5 [1.8-3.9] 1.8 [1.4-2.6] <0.001
CXCR4 (Mon1) 14 [12-16]‡ 12 [11-15] 13 [12-16]‡ 11 [8.7-13] <0.001
CXCR4 (Mon2) 19 [16-24]‡ 18 [14-25] 18 [15-26]‡ 14 [10-20] 0.001 
CXCR4 (Mon3) 6.7 [5.4-8.7]‡ 5.1 [4.0-7.3]‡ 5.6 [4.0-7.7]‡ 3.2 [2.4-5.4] <0.001
Tie2 (Mon1) 6.1 [5.0-7.6]†‡ 5.0 [4.3-6.4]‡ 4.3 [2.5-5.2] 1.9 [1.6-4.9] <0.001
Tie2 (Mon2) 10 [7.9-15]‡ 11 [7.6-15]‡ 7.6 [4.4-12] 3.6 [2.2-10] <0.001
Tie2 (Mon3) 8.2 [6.0-10]‡ 8.0 [6.8-10]‡ 7.1 [5.6-8.5] 5.7 [4.6-8.3] 0.001 
 
*p<0.05 vs. grp.2 CD<50 group (p<0.01 for the surface markers), †p<0.05 vs. grp.3 HCs (p<0.01 for 
the surface markers), ‡p<0.05 vs. grp.4 NCs (p<0.01 for the surface markers).   
ANOVA with Tukey’s post-hoc test (normal data) or Kruskal-Wallis text with Dunn’s post-hoc test 
(non-normal data). Data are presented as mean [standard deviation] for normal data or median 
[interquartile range] for non-normal data. CD>50, carotid disease ≥50% and CAD; CD>50, carotid 
disease <50% and CAD; IL6R, interleukin 6 receptor; Mon1, CD14++CD16-CCR2+ monocytes; 
Mon2, CD14++CD16+CCR2+ monocytes; Mon3, CD14+CD16++CCR2- monocytes; TLR4, toll-like 
receptor 4; VEGF, vascular endothelial growth factor; HC, hypercholesterolaemic controls; NC, 
normocholesterolaemic controls. 
  
But Mon3 were also increased in grp.2 CD<50 compared with grp.3 HCs (p<0.01). 
MPA were higher in grp.2 CD<50 than in both grp.1 CD>50 (p<0.001) and grp.4 NCs 
(p<0.001). The grp.2 CD<50 group showed increased expression of CCR2 on Mon3 
(p=0.002 vs. grp.4 NC); IL6R on Mon1 and Mon2 (p<0.001 vs. grp.4 NC); TLR4 on 
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Mon1 (p<0.001 vs. grp.3 HC), Mon2 (p<0.001 vs. grp.3 HCs, p<0.01 vs. grp.4 NCs), 
and Mon3 (p<0.001 vs. grp.4 NC); VEGF receptor 2 on Mon3 (p<0.01 vs. grp.3 HC); 
CXCR4 on Mon3 (p<0.01 vs. grp.3 HC); Tie2 on all subsets vs. grp.4 NC (p<0.001 
for Mon1 and Mon2, p<0.01 for Mon3). Patients from the grp.2 CD<50 had the 
highest of all groups expression of CD49d on all monocyte subsets (p<0.01 for all). In 
contrast to grp.1 CD>50, monocyte CD16 expression was not changed in grp.2 
CD<50 patients. 
 
In univariate regression analysis, higher Mon1 counts were predictive of degree of 
maximal CD (p<0.001), whilst there was modest predictive value for Mon3 (p=0.03) 
and a non-significant trend for Mon2 (p=0.06). 
 
Table 9: Linear regression analysis for predictors of carotid stenosis and intima-
media thickness. 
Stenosis* Intima-media thickness†  Predictor  
(n=160) B [SE] β p B [SE] β p 
Univariate analysis  
Age 0.6 [0.2] 0.21 0.01 0.01 [0.00] 0.36 <0.001 
Male gender 12 [3] 0.26 <0.001 0.05 [0.02] 0.19 0.02 
Systolic BP -0.1 [0.1] -0.09 0.23 0.00 [0.00] 0.00 0.96 
BMI -0.6 [0.3] -0.16 0.04 0.00 [0.00] -0.03 0.70 
CAD 32 [2] 0.74 0.000 0.05 [0.02] 0.21 0.01 
Hypertension 14 [3] 0.32 0.000 0.02 [0.02] 0.09 0.28 
Diabetes 23 [5] 0.33 0.000 0.05 [0.03] 0.13 0.11 
Smoking 13 [4] 0.26 0.001 0.04 [0.02] 0.14 0.08 
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Aspirin 28 [3] 0.65 0.000 0.06 [0.02] 0.23 0.01 
ACEI/ARB 21 [3] 0.44 0.000 0.05 [0.02] 0.17 0.03 
Statin 32 [2] 0.74 0.000 -0.01 [0.01] -0.04 0.62 
Cholesterol -2.8 [1.1] -0.20 0.01 -0.01 [0.01] -0.13 0.10 
eGFR -0.20 [0.17] -0.09 0.24 -0.001 [0.001] -0.07 0.40 
Mon1 0.04 [0.01] 0.26 <0.001 0.000 [0.000] 0.16 0.05 
Mon2 0.11 [0.06] 0.15 0.060 0.001 [0.000] 0.17 0.03 
Mon3 0.15 [0.07] 0.17 0.030 0.001 [0.000] 0.13 0.11 
MPA 0.01 [0.03] 0.03 0.68 0.000 [0.000] 0.10 0.24 
Multivariate analysis*  
Mon1 0.02 [0.01] 0.15 0.04 0.03 [0.01] 0.19 0.02 
Mon2 0.05 [0.05] 0.06 0.36 0.06 [0.06] 0.08 0.27 
Mon3 -0.01 [0.06] -0.02 0.82 0.06 [0.07] 0.06 0.41 
MPA -0.02 [0.03] -0.04 0.53 0.00 [0.03] -0.01 0.92 
*Adjusted for age, sex, hypertension, diabetes, smoking, cholesterol level for multivariate analysis. 
†For multivariate analysis, adjusted for age, gender, smoking for multivariate analysis 
ACEI/ARB, angiotensin converting enzyme inhibitor/angiotensin receptor blocker; B, coefficient of 
regression; BMI, body mass index; BP, blood pressure; CAD, coronary artery disease; eGFR, 
estimated glomerular filtration rate; IMT, intima-media thickness, Mon1, CD14++CD16-CCR2+ 
monocytes; Mon2, CD14++CD16+CCR2+ monocytes; Mon3, CD14+CD16++CCR2- monocytes; 
MPA, monocyte-platelet aggregates; SE, standard error. 
  
In multivariate regression analysis only high Mon1 counts remained a significant 
predictor of CD (p=0.04). Mon1 was a significant predictor of IMT on multivariate 
analysis (p=0.02). 
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4.4.2. Monocyte subsets and plaque neovascularisation 
 
From the whole study population, 128 subjects had atherosclerotic plaques suitable 
for assessment of intraplaque neovascularisation.  
 
Table 10: Demographic and clinical characteristics of patients with different 
grades of plaque neovascularisation 
  
Grade 0 
(n=42) 
Grade 1 
(n=54) 
Grade 2 
(n=32) p value 
Age, years 68 [8] 71 [8] 68 [8] 0.18 
Gender (male), n [%] 24 [57] 32 [59] 23 [72] 0.39 
Systolic BP, mmHg 141 [19] 146 [21] 136 [24] 0.13 
BMI, kg/m2 29 [7]* 26 [5] 27 [5] 0.036 
Cholesterol, mmol/L 4.4 [1.6] 4.3 [1.3] 4.9 [1.8] 0.21 
eGFR, mL/min/1.67 75 [10]* 71 [10] 69 [8] 0.030 
CAD, n [%] 22 [52] 37 [69] 19 [59] 0.27 
Hypertension, n [%] 18 [43] 25 [46] 18 [56] 0.50 
Diabetes, n [%] 6 [14] 5 [9] 6 [19] 0.44 
Current smokers, n [%] 10 [24] 19 [35] 8 [25] 0.41 
Aspirin, n [%] 19 [45] 36 [67] 20 [63] 0.074 
ACEI/ARB, n [%] 11 [26] 20 [37] 12 [38] 0.46 
Statins, n [%] 22 [52] 37 [69] 19 [59] 0.27 
Grade 0 = no detectable intraplaque neovascularisation 
Grade 1 = neovascularisation (mild) 
Grade 2 = neovascularisation (severe) 
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P<0.05 vs. Grade 2. Continuous data are presented as mean [standard deviation] for normal data or 
median [interquartile range] for non-normal data. ACEI/ARB, angiotensin converting enzyme 
inhibitor/angiotensin receptor blocker; BMI, body mass index; BP, blood pressure; CCA, common 
carotid artery; eGFR, estimated glomerular filtration rate.  
 
The Grade 0 group has slightly higher body mass index (BMI) and estimated 
glomerular filtration rate (eGFR) then Grade 2 group (p=0.03 for both).  Patient with 
Grade 2 neovascularisation had higher Mon1 count compared to those with Grade 0 
(p=0.048 for ANOVA and p=0.06 for post-hoc analysis) on multivariate analysis. 
 
Table 11: Monocyte subsets and plasma markers of angiogenesis in patients with 
different grades of plaque neovascularisation 
  
Grade 0 
(n=42) 
Grade 1 
(n=54) 
Grade 2 
(n=32) p 
Counts of monocyte subsets and MPAs 
Mon1, per µL 406 [124]* 464 [150] 482 [149] 0.048 
Mon2, per µL 42 [23-59] 32 [23-60] 34 [29-54] 0.71 
Mon3, per µL 50 [36-71] 57 [40-77] 48 [35-74] 0.44 
MPA, per µL 82 [60-126] 94 [57-142] 99 [77-137] 0.33 
Monocyte surface markers 
CCR2 (Mon1) 155 [37] 149 [34] 165 [37] 0.14 
CCR2 (Mon2) 122 [30] 114 [30] 127 [35] 0.13 
CCR2 (Mon3) 16 [2] 15 [2] 16 [2] 0.67 
CD14 (Mon1) 1398 [344] 1353 [292] 1334 [276] 0.65 
CD14 (Mon2) 1343 [357] 1321 [365] 1321 [366] 0.95 
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CD14 (Mon3) 156 [38] 154 [38] 161 [50] 0.73 
CD16 (Mon1) 11 [3] 10 [2] 10 [2] 0.02 
CD16 (Mon2) 61 [12] 58 [15] 61 [16] 0.59 
CD16 (Mon3) 178 [64] 150 [60] 161 [56] 0.09 
IL6R (Mon1) 67 [23] 69 [22] 74 [17] 0.36 
IL6R (Mon2) 59 [21] 61 [20] 65 [15] 0.37 
IL6R (Mon3) 39 [15] 35 [10] 37 [9] 0.19 
TLR4 (Mon1) 2.9 [1.6-5.1] 4.5 [1.8-5.9] 3.3 [1.6-5.6] 0.05 
TLR4 (Mon2) 3.6 [1.3-7.8] 6.2 [1.6-12] 3.3 [1.3-10] 0.07 
TLR4 (Mon3) 1.7 [1.3-3.0] 2.6 [1.4-3.9] 1.8 [1.3-3.2] 0.06 
CD49d (Mon1) 10 [6.1-18] 11 [7.1-18] 11 [8.1-17] 0.74 
CD49d (Mon2) 21 [12-39] 24 [15-35] 24 [14-32] 0.67 
CD49d (Mon3) 29 [22-47] 34 [25-52] 37 [24-52] 0.41 
VEGF receptor 2 (Mon1) 6.5 [5.0-7.5] 5.5 [4.2-7.2] 6.1 [5.2-6.9] 0.13 
VEGF receptor 2 (Mon2) 10.4 [8.3-15] 10 [7.4-15] 10.5 [7.9-15] 0.80 
VEGF receptor 2 (Mon3) 2.9 [2.1-4.1] 2.9 [2.1-3.8] 3.0 [2.3-4.0] 0.93 
CXCR4 (Mon1) 12 [11-15] 13 [11-15] 13 [11-16] 0.47 
CXCR4 (Mon2) 17 [13-23] 19 [16-26] 18 [15-23] 0.16 
CXCR4 (Mon3) 4.7 [3.8-6.3] 5.7 [4.4-8.5] 6.4 [3.9-7.6] 0.12 
Tie2 (Mon1) 4.8 [3.8-6.4] 5.0 [3.9-7.1] 5.0 [4.2-6.1] 0.70 
Tie2 (Mon2) 8.3 [5.7-14] 10 [7.0-15] 10 [6.8-12] 0.45 
Tie2 (Mon3) 7.3 [5.7-8.7] 7.4 [6.0-8.8] 8.4 [6.0-11] 0.28 
Plasma markers of angiogenesis 
Tie 2, ng/mL 139 [106-186] 128 [103-165] 126 [104-163] 0.84 
Angiopoietin 2, ng/mL 2.5 [1.6-3.9] 2.5 [1.6-4.3] 2.2 [1.2-3.9] 0.92 
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VEGF, pg/mLs 5 [0-93] 20 [0-115] 30 [0-225] 0.62 
*p=0.06 vs. Grade 2. ANOVA with Tukey’s post-hoc test (normal data) or Kruskal-Wallis text with 
(non-normal data). Data are presented as mean [standard deviation] for normal data or median 
[interquartile range] for non-normal data. IL6R, interleukin 6 receptor; Mon1, CD14++CD16-CCR2+ 
monocytes; Mon2, CD14++CD16+CCR2+ monocytes; Mon3, CD14+CD16++CCR2- monocytes; 
MPA, monocyte-platelet aggregates; TLR4, toll-like receptor 4; VEGF, vascular endothelial growth 
factor. 
 
 There were no differences in levels of other monocyte subsets and MPA, nor in 
expression the studied monocyte surface markers at the p<0.01 significance threshold.  
No differences between groups were seen in levels of plasma markers of 
angiogenesis, with no correlation found between their levels and density of the 
correspondent receptors on monocytes. 
 
In univariate regression analysis, predictors of Grade 1 neovascularisation were low 
BMI (p=0.02), smoking (p=0.02), degree of CD (p=0.02) and lower eGFR (p=0.05 
for a trend). 
 
Table 12: Multinomial regression analysis for predictors of plaque angiogenesis 
n=128 Grade 1 vs. Grade 0 
OR [95% CI] 
p Grade 2 vs. Grade 0 
OR [95% CI] 
p 
Univariate analysis 
Age 1.04 [0.99-1.10] 0.11 1.00 [0.94-1.06] 1.00 
Gender 1.09 [0.48-2.47] 0.83 1.92 [0.72-5.12] 0.19 
BMI 0.91 [0.84-0.98] 0.02 0.94 [0.87-1.02] 0.15 
CAD 0.51 [0.22-1.16] 0.11 0.75 [0.30-1.91] 0.55 
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Hypertension 0.87 [0.39-1.96] 0.74 0.58 [0.23-1.48] 0.25 
Diabetes 1.63 [0.46-5.77] 0.45 0.72 [0.21-2.49] 0.61 
Smoking 3.25 [1.21-8.74] 0.02 2.20 [0.95-5.05] 0.06 
Aspirin 0.39 [0.17-0.90] 0.03 0.50 [0.19-1.27] 0.14 
ACEI/ARB 0.60 [0.25-1.46] 0.26 0.59 [0.22-1.60] 0.30 
Carotid stenosis 1.03 [1.01-1.05] 0.02 1.03 [1.00-1.06] 0.03 
Cholesterol 0.94 [0.72-1.24] 0.68 1.20 [0.90-1.60] 0.22 
eGFR 0.96 [0.92-1.00] 0.05 0.94 [0.89-0.99] 0.02 
Mon1 1.00 [1.00-1.01] 0.046 1.00 [1.00-1.01] 0.023 
Mon2 1.00 [0.98-1.01] 0.83 1.00 [0.99-1.02] 0.72 
Mon3 1.01 [0.99-1.03] 0.23 1.01 [0.99-1.03] 0.45 
MPA 1.00 [0.99-1.01] 0.71 1.00 [1.00-1.01] 0.35 
Multivariate analysis 
Mon1* 1.03 [0.99-1.06] 0.11 1.04 [1.01-1.8] 0.022 
Mon1† 1.03 [0.99-1.06] 0.13 1.04 [1.00-1.08] 0.034 
* Adjusted for age, BMI, eGFR, aspirin, statins 
† Adjusted for age, BMI, eGFR, carotid artery disease, aspirin, statins  
ACEI/ARB, angiotensin converting enzyme inhibitor/angiotensin receptor blocker; BMI, body mass 
index; CAD, coronary artery disease; eGFR, estimated glomerular filtration rate; Mon1, 
CD14++CD16-CCR2+ monocytes; Mon2, CD14++CD16+CCR2+ monocytes; Mon3, 
CD14+CD16++CCR2- monocytes; MPA, monocyte-platelet aggregates. 
 
Predictors of Grade 2 neovascularisation were degree of CD (p=0.03), reduced eGFR 
(p=0.02), with a trend seen for smoking (p=0.06). High Mon1 count was significantly 
associated with both Grade 1 (p=0.046) and Grade 2 (p=0.023) neovascularisation. 
On multivariate analysis, Mon1 remained significantly associated with Grade 2 
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neovascularisation after adjustment for age, BMI, eGFR, CD, aspirin and statin use 
(p=0.034). 
 
4.5. Discussion 
 
My study demonstrates for the first time that counts of ‘classical’ monocytes (Mon1) 
is the only monocyte subset associated with severity of carotid atherosclerosis 
independently of other risk factors. This subset was also the only monocyte subset 
which counts were predictive of IMT, a marker of carotid and generalised 
atherosclerosis.(Bots and Grobbee, 2002, Nambi et al., 2012) 
 
Despite some controversy in respect to the link between the total monocyte count and 
carotid atherogenesis, overall, the published data support the role of monocytosis in 
carotid atherogenesis.(Johnsen et al., 2005, Huang et al., 1996) In 2011, Hoogi et al, 
was able to demonstrate a clear correlation between the findings of neovascularisation 
on carotid contrast ultrasound and histological analysis. (Hoogi et al., 2011) In a 
prospective study of subjects free from carotid disease during a 10-year follow up, 
total monocyte count was significantly predictive of future plaque 
development.(Johnsen et al., 2005) Until now it has been unclear which of the 
monocyte subsets were principally implicated in the process.  
 
Of interest Mon3 monocytes (i.e., ‘non-classical’ monocytes) which were previously 
shown to be increased in stable CAD were only significantly increased in patients 
with moderate, but not with severe, carotid stenosis in the present study.(Schlitt et al., 
2004) The exact reasons of this difference I cannot fully explained based on design of 
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the present study but it could be due to predominant role of the subset in the initial 
development and growth of atherosclerotic plaques. I also observed a similar 
phenomenon in relation to expression of CD49d by all monocyte subsets (i.e.. a 
receptor that mediates recruitment of monocytes to areas of vascular inflammation 
and atherogenesis)(O'Brien et al., 1996) and levels of MPAs (another phenomenon 
contributing to monocyte migration to the vascular tissues).(van Gils et al., 2008) 
Not only numbers of monocytes but also their functional status could play a role in 
atherosclerotic plaque formation. My present study supports this hypothesis by 
demonstrating significant upregulation of different monocyte receptors mediating 
inflammatory and angiogenic processes in the patients with carotid atherosclerosis. 
These changes were not confined to a single monocyte subset but were present 
variably across all 3 monocyte subpopulations, possibly reflecting complex 
implication and functions of different subsets in atherogenesis. Of note, some features 
on excessive proinflammatory activation, such as increased expression of IL6R on 
Mon2 was only seen in grp.1 CD>50 patients suggesting higher degree on monocyte 
proatherogenic changes in subjects prone to more severe coronary atherosclerosis. 
Interestingly, patients with the severe carotid stenosis had highly significant reduction 
in CD16 expression by all monocytes. The presence of this phenomenon does not 
have a straightforward explanation and farther investigation of related changes in 
monocyte functionality may be of interest. 
 
My present study is the first to evaluate the role of monocytes and their subsets in 
carotid plaque neovascularisation and to show a significant and independent 
association of Mon1 subset in development of plaque neovascularisation. Two major 
factors influencing intravascular neovascularisation are local ischaemia and 
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inflammatory burden (either local or systemic). Diffusion of oxygen and other 
nutrients is limited to 100μm from the lumen of the blood vessel, which in normal 
arteries is adequate to nourish the inner media and intimal layers. As vessel wall 
thickness increases in the setting of vascular disease, proliferation of the vasa 
vasorum and intimal neovascularization is observed and the degree of adventitial 
neovascularization is associated with carotid IMT. (Magnoni et al., 2009) The role of 
local ischemia in angiogenesis is supported by evidence of a rabbit model of high 
local levels of hypoxia inducible factor-1, (Bjornheden et al., 1999) which is a 
recognised promoter of production of vascular endothelial growth factor (VEGF). 
(Kuwahara et al., 2002) Consequently, VEGF (a potent stimulator of angiogenesis) is 
able orchestrate a local proangiogenic environment and to mobilise endothelial 
progenitors. Indeed, VEGF is abundantly expressed within atherosclerotic lesions. 
(Inoue et al., 1998) Lack of significant systemic plasma VEGF levels changes could 
be due to the relatively small area of localised carotid plaque angiogenesis. 
 
Hypoxia-independent pathways of angiogenesis within the vessel wall have been 
identified and appear to depend on an inflammatory stimulus.(Carmeliet, 2003) The 
density of intraplaque vessels corresponds to the focal accumulation of inflammatory 
cells (such as monocytes/macrophages) forming a vicious circle: enhanced 
angiogenesis – enhanced mobilization of inflammatory cells – enhanced 
angiogenesis.(Moulton et al., 2003) The present study provides the first clinical 
evidence of pathological carotid intraplaque angiogenesis to ‘classical’ Mon1 subset 
with potent proinflammatory and phagocytic properties. (Shantsila et al., 2011, 
Ziegler-Heitbrock et al., 2010)  
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4.6. Limitations/Future Studies 
 
My study is limited by its observational nature and clinical significance of the finding 
for adverse outcome is still to be established. Characteristics and counts of blood 
monocytes were used as surrogates of monocyte activity i.e.: immunity, angiogenesis, 
reparative processes and atherogenesis (Wrigley BJ, 2011, Shantsila et al., 2011), 
which may differ for their distribution within atherosclerotic plaques. My data are 
obtained from relatively small study population and require further confirmation from 
larger prospective analyses. 
Another limitation of my study is the use of statin by my patients and the pleomorphic 
properties that each of the various statins have on both the atherosclerotic and 
angiogenic pathways. This topic is currently part of my subsequent analysis. 
(Jaipersad AS, 2013b) 
My thesis data suggest that plaque neovascularisation is a process occurring both in 
early and late plaque development indicating that monocyte markers may be 
associated with specific carotid plaque characteristics. The process of an 
asymptomatic plaque progression to a vulnerable plaque remains unclear. Therefore 
carotid plaques could be separated based on their complications (i.e.; ulcerative, 
haemorrhagic) so that an association between monocyte parameters and carotid 
plaque complications. 
 
My study was able to demonstrate the classical monocyte (Mon1) to be predictive of 
IMT and associated with severity of carotid atherosclerosis. However, it also 
demonstrated that the non-classical monocytes (Mon3) were significantly raised in the 
presence of moderate but not severe carotid disease. The significance of these 
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findings could be confirmed in larger scale studies with longer follow up looking at 
the development of carotid plaques to establish associations of the levels of individual 
monocyte subsets. This type of study would help highlight interactions of monocyte 
subsets at various stages of angiogenesis and potentially confirm that specific 
subpopulations are more critical for the plaque rupture acting on the plaque 
neovascularization. 
 
The specific role of the various monocyte subsets in atherosclerotic process still 
remains uncertain. My thesis provides further evidence for a variation in monocyte 
subset presence in those patients with carotid plaque disease and pre-existing CAD. 
However, further studies directed at isolating specific subset types and specifically 
tracing their presence within the carotid plaques, would be of significant value. The 
ability to inhibit or artificially introduce a monocyte subset i.e. Mon1, and observe the 
effect on neovascularisation within carotid plaque could help better understand the 
atherosclerotic process.   
 
4.7. Conclusion 
 
Classical monocytes (Mon1) represent the only monocyte subset predictive of the 
severity of carotid and systemic atherosclerosis, such as carotid IMT, degree CD and 
presence of carotid intraplaque neovascularisation. All monocyte subsets showed 
varying changes in expression of receptors mediating inflammatory, angiogenic and 
remodelling processes in patients with carotid atherosclerosis. These observations 
may have important implications for the pathogenesis of carotid plaque and 
intraplaque angiogenesis. 
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CHAPTER V: THE EFFECT OF STATIN THERAPY WITHDRAWAL 
ON MONOCYTE SUBSETS 
 
5.1. Abstract 
 
Background: Three functionally distinct monocyte subsets have been identified. 
Statins are of undoubted effect in atherosclerosis, and have numerous pleiotropic 
effects that contribute to their clinical success, but the effect of these drugs on 
monocytes subsets is unclear. I hypothesised a beneficial effect of statins on key 
receptor expression by monocyte subsets. 
Material and methods: Effects of temporal (2 weeks) cessation of statin therapy by 66 
patients with stable coronary artery disease on monocyte subsets (CD14++CD16-
CCR2+ (Mon1), CD14++CD16+CCR2+ (Mon2) and CD14+CD16++CCR2- 
(Mon3)]), their aggregates with platelets, and their expression of a number of 
receptors involved in inflammation (IL-6 receptor), adhesion (vascular cell adhesion 
molecule [VCAM]), angiogenesis (vascular endothelial growth factor [VEGF]) and 
repair were assessed by flow cytometry.  
Results: Statin cessation did not lead to any significant changes in absolute numbers 
of monocyte subsets or the degree of their aggregation with platelets. All monocyte 
subsets showed significant downregulation of expression of vascular endothelial 
factor receptor 2, Tie2, and Toll-like receptor-4 (TLR4) (all changes p<0.01). 
Expression of CXCR4 was only reduced in Mon1 cells (p=0.013). There was no 
significant change in the expression of CD14, CD16, CCR4, IL6 receptor and VCAM 
(all p=NS). 
Conclusions: Statin withdrawal does not affect counts of any of monocyte subsets, but 
leads to downregulation of expression of TLR4 and receptors related to angiogenesis 
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on all subsets, as well as a decrease in density of CXCR4 expression on ‘classical’ 
Mon1. These data provide further support of pleiotropic effects of statins and their 
effects monocyte pro-angiogenic and pro-reparative characteristics. 
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5.1. Introduction 
 
Monocyte-derived macrophages play a considerable role in pathogenesis of 
atherosclerosis.(Napoli et al., 1997, Pamukcu et al., 2010) They scavenge and 
accumulate lipids thus contributing to the formation the lipid-laden core of the plaque, 
and release numerous proatherogenic cytokines (such as interleukin-6) and other 
biologically active molecules. Of note, the changes in monocyte phenotype and 
function in atherosclerosis occur before their migration to the tissues whilst still in 
circulation.(Cushing and Fogelman, 1992) Activation of circulating monocytes is well 
documented in both CAD and its complications, such as myocardial 
infarction.(Jugdutt, 2002, Maekawa et al., 2002) A high monocyte count is a strong 
predictor of CAD development as well as poor outcome in patients with myocardial 
infarction. More recently, potentially important differences have been found between 
different functional monocyte subsets in the relation to atherogenesis and 
plaque destabilisation.(Wu et al., 2009, Tsujioka et al., 2009) 
 
Statins have dramatically changed and prognosis of patients with different forms of 
atherosclerosis and have become a paradigm their treatment.(MAAS, 1994) Although 
the main effect of statins is related to inhibition of cholesterol production, numerous 
pleiotropic effects have also been reported.(Koh, 2000, Crisby et al., 2001) For 
example, statins’ capacity to ameliorate low-grade inflammation, common in 
atherosclerosis, helps to improve prognosis in CAD irrespectively of their cholesterol 
lowering action.(Ridker et al., 2005) Better understanding of pleiotropic effects of the 
stains could help to identify novel therapeutic targets. 
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Given the intimate involvement of monocytes in atherogenesis it is natural to explore 
direct effects of statins on monocyte numbers, subsets and phenotypes.(Ferro et al., 
2000, Han et al., 2005) In doing this the differences between individual monocyte 
subsets need to be considered. The most straightforward way of testing this is to 
evaluate monocyte changes after initiations of statins. However, this approach has 
several limitations. Majority of patients diagnosed with CAD simultaneously start 
several treatments potentially affecting monocytes (e.g., angiotensin converting 
enzyme [ACE] inhibitors, aspirin). Also, even if deemed ethical, temporal delay in 
initiation of those medications would only allow assessment short-term effects of 
statins. However, it is known that short-term pleiotropic effects of the statins may be 
profoundly different from the long-term effects, as this is the case with endothelial 
progenitor cells.(Vasa et al., 2001, Hristov et al., 2007)   
 
In this chapter of my thesis, I tested the hypothesis that a beneficial effect of statins on 
monocyte subsets would be seen, as defined by the expression of key surface 
receptors, using a model of the two-week cessation of this drug. 
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5.3 Methods 
 
5.3.1. Study population 
 
I recruited 66 patients with known treated CAD and carotid atherosclerosis confirmed 
by ultrasonography and who attended the Sandwell and West Birmingham Hospitals 
NHS Trust between November 2009 and November 2012 and met the study criteria. 
Exclusion criteria comprised any hospital admissions within preceding 3 months, 
infectious and inflammatory disorders, cancer, significant valvular heart disease, atrial 
fibrillation, renal failure [creatinine levels > 200 µg/mL], immune-modulating drugs 
and hormone replacement therapy. 
 
The study participants were invited to attend the research clinic in the morning, after 
abstaining from smoking from midnight of the preceding day.  Following a 20-minute 
supine rest, a 20 ml blood sample was taken for laboratory analyses. After the 
baseline analysis patients stopped their statin therapy till the second blood sampling 
14 days later, and then resumed. The study was performed in accordance with the 
Helsinki declaration and was approved by the Coventry Research Ethics Committee. 
All participants provided written informed consent. 
 
5.3.2. Flow cytometry  
 
I performed flow cytometry analysis as discussed previously in the main methodology 
section. 
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5.3.3 Statistical analysis 
 
Statistical analysis was performed as I presented in the main methodology section.  
 
5.4. Results 
 
5.4.1. Study population 
 
Sixty-six patients completed the study (aged 70 [8.4] years, 42 [64%] male, body 
mass index 27 [5.1] kg/m2, systolic blood pressure 138 [20]/70 [12] mm Hg, 
estimated glomerular filtration rate 71 [10] ml/min/1.73 m2, and total cholesterol 3.9 
[0.6] mmol/L). Medical records showed previous myocardial infarction in 18 [27%], 
hypertension in 42 [64%], and diabetes in 13 [20%] patients. Current smokers were 
23 [35%] patients. Their medications included aspirin in 60 [91%], clopidogrel in 13 
[20%], beta-blockers in 32 [49%], ACE inhibitors or angiotensin receptor blockers in 
40 [61%] patients. The medications remained the same during the period of the study. 
All patients received long-term treatment with statins before their withdrawal, mostly 
simvastatin (42 [64%] patients) and atorvastatin (16 [24%]). 
 
5.4.2. Monocyte parameters 
 
The statin cessation did not lead to any significant changes in levels of monocyte 
subsets or degree of their aggregation with platelets. 
73 
Table 13: Monocyte parameters before and after statin withdrawal 
 
  Mon1 Mon2 Mon3 
 On statin After statin p value* On statin After statin p value* On statin After statin p value* 
Count, per µL 475 [150] 461 [165] 0.30 36 [29-59] 39 [26-54] 0.40 58 [46-77] 56 [38-76] 0.054 
Monocyte, % 81 [76-86] 81 [75-86] 0.96 7 [5-10] 7 [5-11] 0.82 11 [8-14] 11 [7-14] 0.88 
MPA, per µL 77 [51-116] 79 [45-125] 0.74 11 [7-16] 11 [7-16] 0.30 8 [6-11] 7 [5-11] 0.47 
MPA, % 16 [13-21] 17 [14-22] 0.32 25 [18-40] 28 [19-38] 0.26 13 [11-16] 14 [12-16] 0.29 
CD14, MFI 1350 [262] 1296 [274] 0.10 1378 [348] 1309 [337] 0.11 155 [45] 148 [43] 0.08 
CD16, MFI 10 [3] 10 [3] 0.32 55 [16] 56 [16] 0.32 148 [64] 153 [54] 0.38 
CCR2, MFI 161 [40] 163 [36] 0.62 123 [35] 126 [31] 0.47 16 [2] 16 [2] 0.95 
Toll-like receptor 4, MFI 4.7 [3.6-6.6] 4.0 [3.3-5.0] <0.001 7.5 [4.2-13] 6.1 [4.0-8.8] 0.002 3.0 [1.9-4.0] 2.4 [1.9-3.3] 0.006 
IL-6 receptor, MFI 75 [14] 75 [17] 0.96 67 [12] 68 [15] 0.48 36 [9] 38 [11] 0.08 
VCAM-1 receptor, MFI 12 [9-16] 11 [9-16] 0.85 23 [16-37] 26 [19-34] 0.31 37 [26-54] 37 [31-55] 0.15 
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VEGF receptor 2, MFI 6.3 [5.2-7.3] 5.5 [4.4-6.5] <0.001 12 [8.8-17] 9.6 [7.8-12] <0.001 3.2 [2.6-4.1] 2.8 [2.4-3.6] <0.001 
CXCR4, MFI 13 [11-16] 12 [11-14] 0.013 19 [16-24] 19 [15-21] 0.28 6.0 [4.8-8.3] 5.9 [4.7-7.2] 0.07 
Tie2, MFI 5.7 [5-7] 4.9 [4-6.0] <0.001 10.7 [8-16] 8.5 [7-11] <0.001 8.0 [7-10] 7.2 [6-8] <0.001 
 
 
*Paired T-test or Wilcoxon test. Data are presented as mean [standard deviation] or median [interquartile range]. IL, interleukin; MFI, median fluorescence intensity; Mon1, 
CD14++CD16-CCR2+; Mon2, CD14++CD16+CCR2+; Mon3, CD14+CD16++CCR2-; MPA, monocyte-platelet aggregates; VEGF, vascular endothelial growth factor; 
VCAM-1 receptor, vascular cell adhesion molecule-1. 
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Following statin withdrawal all monocyte subsets showed significant down-regulation 
of expression of VEGF receptor 2, Tie2, and TLR4.  
 
 
Figure 7. Effects of statin cessation on monocyte Tie2 expression 
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Figure 8. Effects of statin cessation on monocyte vascular endothelial growth 
factor receptor 2 expression 
 
Expression of CXCR4 was only reduced on Mon1. There was no significant change 
in monocyte expression of CD14, CD16, CCR4, and receptors to IL6 and VCAM-1.  
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5.4.3. Plasma parameters 
 
The statin withdrawal resulted in significant reduction of plasma Tie2 levels, but did 
not change in VEGF or angiopoietin-2.  
 
Table 14: Plasma angiogenic factors before and after statin cessation 
 On statin After statin p value* 
Tie 2, ng/mL 126 [101-163] 113 [93-143] 0.008 
Angiopoietin 2, ng/mL 2.4 [1.6-4.7] 2.6 [1.8-4.9] 0.11 
VEGF, pg/mLs 20 [0-95] 10 [0-103] 0.60 
*Wilcoxon test. Data are presented as median [interquartile range]. VEGF, vascular endothelial growth 
factor 
 
There was no correlation between monocyte Tie2 density and plasma Tie2 and 
angiopoietin-2 levels, and between monocyte VEGF receptor 2 expression and plasma 
VEGF levels. 
 
Table 15. Correlation analysis of plasma angiogenic factors and monocyte 
receptors 
 Mon1 Mon2 Mon3 
 r p value r p value r p value 
 Monocyte Tie2 expression 
Plasma Tie2 0.07 0.59 0.11 0.40 0.04 0.77 
Plasma 0.00 0.99 0.00 0.98 -0.12 0.32 
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angiopoietin 2 
 Monocyte VEGF receptor 2 expression 
Plasma VEGF 0.03 0.82 0.03 0.84 -0.10 0.44 
VEGF, vascular endothelial growth factor. Mon1, CD14++CD16-CCR2+; Mon2, 
CD14++CD16+CCR2+; Mon3, CD14+CD16++CCR2-. 
 
5.5. Discussion 
 
The main finding of my study is that statin cessation led to significant down-
regulation of receptors involved in angiogenesis on all monocyte subsets. Statin 
cessation was also related to reduction of CXCR4 expression on ‘classical’ Mon1.  
 
Statins are known to modulate angiogenesis with most (but not all) reports indicating 
their pro-angiogenic and pro-reparative properties.(Pourati et al., 2003, Asai et al., 
2012, Zhang et al., 2012, Zaitone and Abo-Gresha, 2012, Koutouzis et al., 2007) Our 
group has previously shown that high-dose atorvastatin increased levels of circulating 
progenitor cells and angiopoietin-2, but reduced plasma VEGF 
concentrations.(Jaumdally et al., 2011, Jaumdally et al., 2010) The pro-angiogenic 
and pro-reparative effects of statins appear to be drug and dose dependent and involve 
numerous pathways.(Camnitz et al., 2012) My findings indicate that overall statin 
treatment is associated with enhancement of monocyte expression of receptors 
involved in these processes. Whilst the effects of statin withdrawal on monocyte 
VEGF receptor 2 and Tie2 were uniform over all monocyte subsets, CXCR4 was only 
decreased on Mon1, with a similar trend for Mon3. No effect was found in relation to 
CXCR4 expression on Mon2, subsets featured by the highest of all subsets expression 
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of the receptor. This could reflect a differential role of monocyte receptors in complex 
CXCR4-mediated inflammatory and reparative effects.(Liehn et al., 2011) However 
the absolute change in the receptor density was small and the results need to be 
interpreted cautiously. 
 
Although, my overall data suggest that statins reduce monocyte TLR4 expression, 
there is some controversy in this regard. Most of the data come from in-vitro 
experiments or studies on healthy normolipidemic volunteers. For instance, 4-week 
administration of 20 mg daily of atorvastatin reduced TLR4 expression in only 12 
healthy subjects with similar effects also seen in vitro.(Methe et al., 2005) However in 
a double-blind, placebo-controlled study on healthy volunteers high-dose simvastatin 
did not influence monocyte surface TLR4 density, but diminished its up-regulation in 
response to endotoxemia.(Niessner et al., 2006) Statins were unable to control TLR4 
over-activation in patients with chronic idiopathic urticaria.(Azor et al., 2011) In a 
study of 140 patients undergoing carotid endarterectomy with half of patients not 
receiving statins, immunohistochemically assessed macrophage density of TLR was 
higher among statin naïve subjects.(Katsargyris et al., 2011) However it is not clear 
whether the findings could be affected by clinical factors on which a decision was 
made about the statin treatment. Admittedly statins differ in relation to their capacity 
to reduce monocyte TLR4 levels, with such properties seen for atorvastatin, but not 
rosuvastatin.(Satoh et al., 2012) Finally the response of monocyte TLR4 to statins is 
affected by genetic polymorphisms.(Boekholdt et al., 2003) Of interest, given the 
recently demonstrated involvement of the TLR4 in pro-angiogenic pathways the 
down-regulation in the receptor after the statin cessation seems to accord with other 
changes in receptors related to angiogenesis.(Grote et al., 2010) Although reasoning 
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for this part of my findings remains unclear, the effects of statins may still be more 
complex than originally thought.  
 
5.6. Limitations/Future Studies 
 
The study population is relatively small, which could result in omission of some 
subtle changes in monocyte parameters. The study was performed over the interval of 
two weeks and does not provide information on shorter-term or longer-term effects of 
statin withdrawal. The study does not analyse functional status on monocytes and 
does not provide mechanistic insight into the findings.  
 
The results of this thesis demonstrate the common notion that statin therapy and its 
pleiotropic effects are generally very complex. Evidently a study of similar design is 
required on a larger scale with a focus mainly on statins to further emphasise the 
results shown in this study. The finding that statin cessation led to a significant down 
regulation of receptors on all monocyte subsets involved in angiogenesis may have 
significant implications on those patients whose statin medication is discontinued for 
clinical and non clinical reasons. 
 
To provide complimentary knowledge to the findings in my study, the effects of 
different statin treatments on modulation of monocyte-associated plaque progression 
and neovascularisation could be investigated. The implications here on monocytes 
and plaque morphology would have immense therapeutic applications. 
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5.7. Conclusion 
 
In conclusion, my study results suggest that statin withdrawal does not affect counts 
of any of monocyte subsets. However, it leads to downregulation of expression of 
TLR4 and receptors related to angiogenesis on all subsets, and decrease in density of 
CXCR4 expression on ‘classical’ Mon1. These data provide further support of 
pleiotropic effects of statins and their effects monocyte proangiogenic and 
proreparative characteristics.  
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CHAPTER VI. SUMMARY AND OVERALL CONCLUSIONS 
 
6.1. Thesis summary 
 
My thesis begins with a review of literature on neovascularisation in plaque growth, 
vasculogenesis, angiogenesis, and then addresses the role of monocytes and their 
subpopulations role in mediating angiogenic signalling. The implication of these 
processes in the presence of atherosclerosis is discussed in section 1.1. The 
importance of monocytes and their role in relation to coronary heart disease and 
carotid plaque disease is emphasised. However, significant gaps remain in 
understanding of the roles of individual monocyte subsets and their functional 
characteristics in systemic and carotid plaque atherogenesis.  
 
The potential of carotid ultrasound and the evolution of CEUS in characterisation of 
carotid atherosclerosis are discussed in section 2.3 and chapter 3. There is growing 
evidence supporting the use of CEUS in the use carotid plaque analysis. In Chapter 3, 
CEUS is used to demonstrate the presence of neovascularisation within the carotid 
plaques. There is an increasing use of contrast ultrasound in experimental research 
and this method is now being applied to the clinical setting. However, the technique is 
still to be validated and standardised for robust use in clinical research. As part of my 
thesis, I present a chapter devoted to the standardisation and assessment of 
agreeability of the method of CEUS for detection of carotid wall neovascularisation.  
 
In Chapter 4, patients with pre-existing CAD and CD were recruited to demonstrate 
differences in monocyte subsets and their expression of inflammatory and angiogenic 
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receptors in relation to CEUS detected carotid plaque neovascularisation. My study 
showed for the first time, that classical monocytes (Mon1) were associated with more 
advanced CD, independent of other risk factors and the same subsets were also linked 
to increased carotid IMT. I also found that non-classical Mon3 subset, known in the 
literature to have reparative potential were increased in stable CAD and moderate CD 
(<50%) but not severe CD (>50%). There was a significant increase in expression of 
monocyte receptors involved in their migration to tissues (i.e., CD49d), and levels 
monocyte-platelet interactions also known facilitate monocyte trans-endothelial 
migration. Interestingly, patients with CD>50% had a significant reduction of CD16 
expression by all monocytes, a trend not easily explained in this study but an 
indication for further monocyte functional studies.  
 
Chapter 5 highlights and contributes to the accumulating evidence on the pleomorphic 
effects of statins. My thesis demonstrates an enhanced monocyte effect in 
angiogenesis on those taking statins, demonstrated by increased expression pro-
angiogenic markers. The main focus of this chapter however, emphasised the effect of 
statin withdrawal (2 weeks) on monocyte subsets and their angiogenic markers. 
Overall, there was no reduction in monocyte counts after statin withdrawal but 
controversially a significant reduction in monocyte expression of TLR4 on all subsets 
and a decrease in CXCR4 on Mon1 was observed. My analysis suggests a complex 
role of statin therapy and modulation of monocyte-mediated inflammation, 
angiogenesis and repair.  
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6.2. Future research 
 
Despite advances in the management of atherosclerosis, progressively aging 
population results in significant number of patients suffering the consequences of 
atherosclerotic disease. A considerable amount of research is being conducted to 
prevent or slow the progression of the carotid artery disease. Due to the complex 
nature of the disease pathology and the intricate pathological processes occurring 
within the arterial walls, further developments in this field would require even better 
understanding of the mechanisms and pathways involved. My thesis has provided 
insight into: 1) the presence of pathological neovascularisation within the 
atherosclerotic carotid plaque; 2) the relationship between the presence of 
neovascularisation and monocyte subsets and their angiogenic receptor expression; 3) 
the relationship of monocyte characteristics to cessation of statin therapy. Several 
questions still however remain unanswered. The following is a framework of studies, 
which could be performed to address these notions.  
 
6.2.1 Carotid Contrast Ultrasound 
 
1. In this thesis study, I have shown a agreeable method of performing CEUS. 
However further research into methods aiming to delineate and quantify 
plaque features would allow for standardisation of technique across multiple 
research centres and potentially for its clinical utilisation in the future. Also, 
MRI and CT modalities are increasingly used to assess CD and these 
techniques with their high specificities and sensitivities would need to be 
assessed against CEUS outcomes. 
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2. Histological characteristics of high risk and ruptured plaques are well 
documented, but methods to visualise these plaques in vivo remain limited. To 
test this, other aspects of plaque morphology i.e.; ulceration, plaque volume 
could be measured in the presence of new onset neovascularisation in 
asymptomatic individuals undergoing long term follow up with the CEUS 
method and to demonstrate the evolution of plaque progression and its 
changes when complications develop. This could perhaps result in a model for 
prediction of atherosclerotic clinical events and shed insight into how these 
varying plaque characteristics interact to cause instability.  
 
3. My thesis presents for the first time, a novel agreeable method of using CEUS 
to detect the presence of neovascularisation within existing carotid plaque. 
Further studies would be required using both histological and novel advanced 
imaging methods, like magnetic resonance imaging (MRI) to test CEUS 
sensitivity and specificity at detecting of the presence of neovascularisation. 
Confirmation of CEUS accuracy would allow for its widespread use as a 
method of detecting neovascularisation, and possibly extending its application 
to directed therapeutic interventions.  
 
6.2.2. Monocyte subsets 
 
1. My thesis data suggest that plaque neovascularisation is a process occurring 
both in early and late plaque development indicating that monocyte markers 
may be associated with specific carotid plaque characteristics. The process of 
86 
an asymptomatic plaque progression to a vulnerable plaque remains unclear. 
Therefore carotid plaques could be separated based on their complications 
(i.e.; ulcerative, haemorrhagic) so that an association between monocyte 
parameters and carotid plaque complications. 
 
2. My study was able to demonstrate the classical monocyte (Mon1) to be 
predictive of IMT and associated with severity of carotid atherosclerosis. 
However, it also demonstrated that the non-classical monocytes (Mon3) were 
significantly raised in the presence of moderate but not severe carotid disease. 
The significance of these findings could be confirmed in larger scale studies 
with longer follow up looking at the development of carotid plaques to 
establish associations of the levels of individual monocyte subsets. This type 
of study would help highlight interactions of monocyte subsets at various 
stages of angiogenesis and potentially confirm that specific subpopulations are 
more critical for the plaque rupture acting on the plaque neovascularization. 
 
3. The specific role of the various monocyte subsets in atherosclerotic process 
still remains uncertain. My thesis provides further evidence for a variation in 
monocyte subset presence in those patients with carotid plaque disease and 
pre-existing CAD. However, further studies directed at isolating specific 
subset types and specifically tracing their presence within the carotid plaques, 
would be of significant value. The ability to inhibit or artificially introduce a 
monocyte subset i.e. Mon1, and observe the effect on neovascularisation 
within carotid plaque could help better understand the atherosclerotic process.   
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6.2.3 Statins 
 
1. The results of this thesis demonstrate the common notion that statin therapy 
and its pleiotropic effects are generally are very complex. Evidently a study of 
similar design is required on a larger scale with a focus mainly on statins to 
further emphasise the results shown in this study. The finding that statin 
cessation led to a significant down regulation of receptors on all monocyte 
subsets involved in angiogenesis has profound implications on those patients 
whose statin medication is discontinued for clinical and non clinical reasons. 
2.  To provide complimentary knowledge to the findings in my study, the effects 
of different statin treatments on modulation of monocyte-associated plaque 
progression and neovascularisation could be investigated. The implications 
here on monocytes and plaque morphology would have immense therapeutic 
applications. 
 
Further research is also needed to establish the role of genetic polymorphism of 
monocyte subset receptors in the development of plaque progression to symptomatic 
disease. This will help to understand roles of particular monocyte subsets in the 
development of atherosclerotic disease and plaque instability. Also, future studies are 
needed on the relationship of familial hyperlipidaemia and monocyte subset levels in 
the development of atherosclerotic disease whilst taking into account for monocyte 
differences in respect to the receptor expression in familial hyperlipidaemia.  
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6.3. Overall conclusion 
 
New vessel formation within atherosclerotic plaques plays a significant role in the 
clinical presentation of CAD and cerebrovascular events. Blood monocytes play a 
role in both ischaemia and inflammation, two processes implicated in angiogenesis. 
The use of CEUS in my study demonstrates a feasible method to assess carotid plaque 
for the presence of neovascularisation and standardises how CEUS should be 
performed for research purposes. My analysis further advances one’s understanding 
of the role of monocyte subsets and their potential individual characteristics in 
patients with pre-existing CAD and CD. In particular it has produced evidence of the 
role of Mon1 as a predictor of severity of CD. My thesis also provides further insight 
into the pathological process occurring in the atherosclerotic plaque by demonstrating 
varying degrees of expression of monocyte receptors mediating angiogenesis, and 
inflammation from all monocyte subsets.  
 
Statin usage in clinical practise remains the mainstay of prevention against the 
atherosclerotic process. My study begins to explore the relationship between statins 
and carotid plaque in the presence of pre-existing CAD whose prescribed statins were 
stopped. My study findings demonstrate that although statin withdrawal for 2 weeks 
does not affect monocyte subsets, it down-regulates expression of receptors involved 
in: angiogenesis (Tie2), and inflammation (TLR4), on all monocyte subsets. 
Interestingly, reparative receptor expression (CXCR4) was only decreased on Mon1.  
My findings not only lends to the current understanding of affects of statin therapy in 
high-risk atherosclerotic patients but also contributes to the complexity of statin 
effects on the atherosclerotic processes occurring at the molecular level.  
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These observations presented in my thesis on monocytes and subpopulations in 
relations to neovascularisation and statin therapy usage, offer hope for the better 
understanding of the intricate mechanisms occurring during the atherosclerotic 
process in the presence of CAD and CD. But the limitations of the experimental 
models involved need careful consideration before extrapolating to the clinical 
scenario.  
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Appendix 1: PRISMA Checklist 
 
 
PRISMA 2009 Checklist 
 
 
 
Moher D, Liberati A, Tetzlaff J, Altman DG. (2009). Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses: The PRISMA Statement. . Available: 
http://www.prisma-statement.org/2.1.2%20-%20PRISMA%202009%20Checklist.pdf. 
Last accessed 13th August 2011. 
 
 
 
 
Section/topic   Checklist item  
METHODS  
Eligibility criteria  Specify study characteristics (e.g., PICOS, length of follow-up) and report 
characteristics (e.g., years considered, language, publication status) used as criteria 
for eligibility, giving rationale.  
Information sources  Describe all information sources (e.g., databases with dates of coverage, contact 
with study authors to identify additional studies) in the search and date last 
searched.  
Search  Present full electronic search strategy for at least one database, including any limits 
used, such that it could be repeated.  
Study selection  State the process for selecting studies (i.e., screening, eligibility, included in 
systematic review, and, if applicable, included in the meta-analysis).  
Data collection process  Describe method of data extraction from reports (e.g., piloted forms, 
independently, in duplicate) and any processes for obtaining and confirming data 
from investigators.  
Data items  List and define all variables for which data were sought (e.g., PICOS, funding 
sources) and any assumptions and simplifications made.  
RESULTS  
Study selection  Give numbers of studies screened, assessed for eligibility, and included in the 
review, with reasons for exclusions at each stage, ideally with a flow diagram.  
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Appendix 2: PRISMA Flow Diagram 
 
PRISMA 2009 Flow Diagram 
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Moher D, Liberati A, Tetzlaff J, Altman DG. (2009). Preferred Reporting 
Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. 
. Available: http://www.prisma-statement.org/2.1.4%20-
%20PRISMA%202009%20Diagram.pdf. Last accessed 13th August 2011. 
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Appendix 3: SOP Carotid Ultrasound 
STANDARD OPERATING PROCEDURE CUPNASA 
Carotid Contrast Ultrasound protocol 
Written by A. Jaipersad, A. Shantsila, E. Shantsila 
N.B. Use of the Phillips GX50 is forbidden  
Without having been officially trained 
Required pre-training 
1. SOPs on venepuncture and on good clinical practice 
Contents 
Introduction 
Brief Description of method 
Standard and contrast-enhanced carotid ultrasound imaging 
 
Contrast Preparation 
 
Procedure 
                        Participant Preparation 
                            Machine Set-up, Probe Frequency and Magnification 
                            Anatomical Sites of Interest 
                        2D Procedure 
                   Contrast Procedure 
Analysis of Images 
                          Intima Media Thickness 
                          Parameters to analyse 
                          Plaque morphology analysis 
                          Stenosis 
                          Contrast image analysis 
References 
 
Introduction 
 
 
Vasa Vasorum (VV) is known to be prominent in areas of atherosclerosis and 
contribute to vascular wall nutrition.1 Their development not only contributes to 
structural properties of the arterial wall but they have been implicated in various 
pathological processes; inflammation, hemorrhage and plaque rupture.2 
Imaging strategies for VV are currently limited. B mode ultrasonography is the gold 
standard in measuring plaque structure but lacks detail when looking at 
neovascularization. Contrast Ultrasound (CU) has now been for sometime utilized for 
use in the cardiology setting. Contrast enhanced ultrasound for carotid plaque 
enhancement although first documented in the literature over 10 years ago, recently 
has emerged as a method that is easy, feasible and reproducible. Currently however, 
the analysis remains less quantitative and more subjective. The aim of the SOP is to 
document the methodology in obtaining CEUS images.   
  
 
Brief Description of method 
 
Magnified, gray scale and contrast images of the carotid artery at three levels on 
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bilaterally of each participant are to be obtained. The segments to be imaged are the 
distal common carotid artery, the carotid bifurcation, and the proximal internal carotid 
artery. Images should be acquired with the participant’s head rotated 45 degrees away 
from the side of study. A single image ought to be captured at the common carotid 
level of the artery and two images each from a different angle must be captured of 
both the carotid bifurcation and the internal carotid artery. Three ml of Sonovue 
contrast are to be delivered via an infusion pump at a rate 1.3ml/sec.  A video stream 
of the common carotid artery will be recorded and will be accompanied by a 2 to 4 
second real-time cine loop demonstrating at least three complete cardiac cycles. In 
addition, the common carotid, the carotid bifurcation and internal carotid segments 
will be captured as a single or static image. All static images should be captured at 
end-diastole. Captured images should visualize the intima-media complex of the far 
wall of each segment studied over a 1-cm length of the artery. 
 
 
Standard and contrast-enhanced carotid ultrasound imaging. 
 
First, the carotid bifurcation is imaged bilaterally by B-mode ultrasound, color 
Doppler, and pulsed-wave Doppler, and the examination is digitally stored for later 
review. Special care is to be taken to image and record all distinct plaques seen at 
each side.  
The patient is then submitted to contrast-enhanced ultrasound imaging, with special 
attention to the previously identified lesions. The preset real-time, contrast-specific 
imaging modality is switched on and image settings adjusted to maximize contrast 
signal visualization. 
 
The contrast ultrasound investigation is performed with an infusion in an antecubital 
vein (20 Gauge Venflon) of Sonovue 6mL (Bracco), at a rate of 1.3ml/sec. The linear 
array probe with a mechanical index 0.08 to 0.10, with contrast pulse sequencing 
continuous real-time recording is used to achieve the best visualization of the plaque 
morphology and vascularization. Good images can be obtained for about 3 minutes. 
For a single examination, no more than 2 vials of Sonovue are required. The studies 
are to be digitally stored for later analysis by pressing end exam button. The patients 
are to be observed for 30 min before returning to their wards/home.  
 
Carotid assessment in patients with systolic blood pressure above 160 mm Hg has 
limited information and should be avoided. Never attempt to do the test when BP 180 
mmHg or above as documented by Sonovue. 
 
Contrast Preparation:  
 
Required:  
1. BRACCO VUEJECT (BR-INF100) Infusion Pump with wired screen  
      remote. 
2. Kit for Balancing pump through Echo- Contrast 
                    Consists of: -    20ml Syringe 
- Intra venous Cannula 20G 
- Infusion Line 
 
3. 2X BRACCO Sonovue: sulpher hexafluoride microbubbles 8 microlitres/ml 
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powder and solvent for dispersion.  
                           Consists of: -   Vial with 25mg lyophilized powder 
- 1 pre-filled syringe containing 0.9% sodium  
chloride with separate piston. 
-     1 spike transfer system. 
Preparation of Contrast: 
1. Switch on infusion pump by pressing ON/OFF button on 
machine. System will run through pre-checks. Once 
completed, screen will request to insert syringe and 
close cover.  
NOTE: This process takes time. Perform prior to preparing 
contrast material.  
2. Open all material as listed above. 
3. Remove cap from power vial and connect to spike 
system. An audible click can be heard.  
4. Connect piston to pre-filled syringe and connect to spike 
system with twist motion.  
5. Reconstitute power with sodium chloride by depressing 
piston. 
6. Disconnection pre-filled syringe and connect 20ml 
syringe. Fill 20ml syringe and depress back into powder 
vial multiple times to remove all traces of powder 
residue in vial. 
7. Remove filled 20ml syringe and connect to line. Flush 
line to remove air.  
8. Place filled 20ml syringe and prepped line into infusion 
machine, being careful to feed line into machine.  
9. Close cover. 
10. Infusion System will then run through a checking cycle 
which if correct will cycle the inserted syringe. A 
countdown timer will appear on the remote.  
11. The contrast is now prepared and ready to be used. 
Note: We do not connect the line to the patient until all B-
mode images are taken (steps 5-13 as listed below). 
 
Procedure 
 
Participant Preparation: 
 
The carotid ultrasound procedures should be performed with the subject in the supine 
position with a 20G intra venous cannula placed. The subject is made comfortable in a 
position that allows head rotation to either side. The imager stands or is seated at the 
end of the exam table near the participant’s head. The top of the head should be about 
three inches from the end of the exam table and the head is to be rotated 45 degrees 
away from the side being scanned. 
 
a. Allow the subject to rest in the room for about 20 minutes before scanning 
b. Helps to remove patient jewellery and protect clothing with paper provided. 
c. Explain details of the procedure and possibility of allergic reaction. 
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Turn machine ON by pressing ON/OFF button. 
Note: - Turning U/S on and will automatically load Carotid contrast Protocol.  
            (Also available by pressing PROTOCOL on machine) which starts in  
             B-mode and must be switched to Contrast on mode by the button at   
             the top of the machine (shown on screen).  
 
            Machine Set-up, Probe Frequency and Magnification 
Pre-sets have been defined for the Philips GX50 device. The settings will be set at the 
start of the study by the Phillips engineer and should not be altered. Each machine 
will have only one probe. The probe that is used for the scan is L12-3. The probe 
frequency is set to 3 to 12 MHz for scanning the common carotid artery and the 
internal carotid artery.   
 
Philips GX50 Carotid Contrast Ultrasound Pre-sets  
Frequency:  26Hz  
66 Dyn Range  
Res  
Edge 3  
Map G 
Ave. 2  
Depth 3cm 
 
 
- Pressing ACQUIRE will save the image to the active memory and show 
on the right of the screen the image captured.  
- Automatic return to B-Mode, if not press 2D button to return. 
- Only pressing END EXAM will save to the hard drive. 
 
 
Participant information should be entered on the ultrasound machine’s demographic 
information screen to identify the scan as a Vascular Contrast scan.  
 
To enter subject information to GX50 demographic information screen:  
 
Press PATIENT on the machine.  
 
The participant ID number is entered in the MRN section.  
Hit "Return tab" until you reach the Last Name field, repeat to enter forename, date of 
birth, sex and activate pull down menu for scan type: “Vascular”. 
Hit the OK to begin scanning. 
 
1. Position patient on bench lying down with head up and neck stretched 
exposing area to scan (as above). 
2. Place Stickers for ECG as labelled on Leads (Red [Right} Yellow [Left] 
Green [Front] diagram on leads. 
3. Pressing PHYSIO button on U/S will toggle between ECG leads.  
4. Turn room Lights off.  Scanning is now ready to begin.  
Anatomical Sites of Interest 
 
The extra cranial carotid arteries are the largest arteries in the neck. The right 
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common carotid artery originates from the innominate artery on the right and the left 
common carotid artery originates directly from the aortic arch. Each common carotid 
artery ascends in the neck lateral to and posterior to the trachea. At the approximate 
level of thyroid cartilage, slightly below the angle of the mandible, the common 
carotid artery bifurcates into the external and internal carotid arteries 
 
According to standard protocol the carotid ultrasound image is captured in static grey-
scale and real-time cine loops from the common carotid, bifurcation and internal 
carotid on both the right and the left side.  
 
1. Distal common carotid: the 1 cm segment of the common carotid artery proximal to 
the origin of the carotid bifurcation, where the near and far walls of the artery are 
parallel to one another. The common carotid artery dilates just before bifurcating into 
the internal and external carotid arteries. 
 
2. Carotid bifurcation: for study purposes this arterial segment is defined as the flow 
divider extending into the proximal internal carotid artery. It ends when the walls of 
the artery lose their curvature and become parallel.  
 
3. Internal carotid artery: anatomically, the tip of the bifurcation defines the proximal 
end. The vessel then ascends in the neck and enters the base of the skull. The internal 
carotid artery has no branches in the neck. For the purposes of this protocol, the study 
will be limited to the initial 10 mm of the internal carotid artery distal to the 
bifurcation.   
 
4. External carotid artery: originates at the carotid bifurcation and is more superficial 
and nearer the mid- line than the internal carotid. The external carotid artery lies 
anterior and slightly medially to the internal carotid artery in 90% of individuals. The 
external carotid artery is usually smaller than the internal and it has branches that 
supply the neck and face, the first branch is usually identified as the superior thyroid 
artery. No images of the external are recorded.  
 
2D Procedure: 
 
5. Put contact gel onto probe and starting with Right side, identify Common 
Carotid artery. Press TEXT button to label scan image (drop down menu) 
with appropriate side. 
6. Use GAIN button to improve image. 
7. Press Freeze to still the image and adjust using trackball in accordance with 
ECG (the peak R wave). Press ACQUIRE once satisfactory image is 
obtained.  
8. Press Zoom button and adjust box size and position using trackball. Use right 
button to toggle between. 
9. Press M-mode button and position cursor with trackball. Press M-mode again 
to activate (which will display two images; left M-mode and right B- mode) 
and Freeze followed by ACQUIRE to save image. Automatic return to B-
Mode, if not press 2D button to return. 
10. Press PW (Pulse Wave) button to activate doppler and position indicator using 
trackball and press PW to activate and acquire pressure readings. (If does not 
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work press HQ button to activate. Confirm angle is 60 degrees. Press Acquire 
to save. Automatic return to B-Mode, if not press 2D button to return.  
11. To measure: press Calliper button i.e. small lesions and use trackball to 
adjust. ACQUIRE to save. Automatic return to B-Mode, if not press 2D 
button to return. 
12. Pressing CALC button will produce a drop down menu: to calculate percent 
stenosis based on true diameter (lumen to lumen) and residual diameter 
measurements. Carotid image view must be in cross section. Choose CCA or 
ICA as required. Adjust using trackball. Press Acquire to save. Automatic 
return to B-Mode, if not press 2D button to return. 
13. Repeat steps 5-8, 10-12 to acquire images of Carotid Bulb, Plaque if present 
and Internal Carotid Artery.  
14. Repeat steps 5-12 and 13 for Left side. 
Contrast Procedure: 
15.  Press PURGE on Infusion machine to prep infusion line.  
   ALL infusion adjustments can be now made using wired remote. 
16.  Press START and adjust rate of infusion (1.3ml/s) by pressing ARROW 
buttons. This will allow 3 minutes of scanning to be performed with a 1 
minute remaining audible warning and automatic shut off. Pressing OFF on 
remote or infusion machine will shut off, as well.  
17.  On GX50 press Contrast ON button (identified at the bottom of the screen) 
to switch on contrast identification mode. 
18. Begin scanning starting with Patient Right Side.   
19.  Repeat steps: 5-8 and 13 to acquire detail images. 
20.  Repeat steps 5-8 for Left side. 
21. Once finished, press END EXAM. This will save patient data with images on 
hard drive into folder.  
22.   The patient is observed for 5 minutes with ECG leads in place while infusion 
pump is disconnected.  Then ECG leads are removed with pads. 
NOTE: Blood pressure is taken if patient feels ill effects and ECG leads                                      
remain on for 15 minutes.  
23.  The intravenous cannula is removed and pressure applied to site with the 
patient now sitting up and reviewing scan images with imager.  
24. The patient is observed for 15minutes after procedure.  
25. Pressing OFF on the machine will switch off safely.  
 
Analysis of Images: 
 
Using Xcelera and Qlab version 7.1 by Philips Healthcare.  
1. Connect GX50 to Ethernet cable of Xcelera computer. 
2. Switch GX50 on. Machine will warm up.  
3. Press Review button. This will bring up a list of folders on hard drive. If not, 
using trackball at top of screen click on export icon. This will change screen.  
4. Select folder to export and select export at bottom of screen. This will take 
sometime to complete. No message will be given to tell when complete but 
next to study will be a red export icon.  
NOTE: On the right side of screen (TOP) will be a menu to toggle between 
Xcelera export and DVD export. Check to make sure Xcelera is chosen.  
5.   Main computer can now be used to analyse study.  
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6. With Xcelera open as per standard. Enter MRN details as entered earlier on 
GX50 to identify folder and load images.  
7. Toggle images with mouse.  
8. Once image is selected, right click mouse button to open Q-lab for Intima 
Media Thickness (IMT) or double click to open Dicomm viewer to measure 
parameters as below.  
Note: At top to viewer, make sure carotid protocol is selected from drop down 
menu. This allows measurements to be performed.   
 
Intima Media Thickness 
Measured in Qlab as an automated procedure by clicking IMT icon listed on left. 
If automation unclear adjustment can be made using the icons listed on the left of 
the screen, taking care to keep the 10mm distance required and criteria as well 
established in the literature. Anterior wall IMT is measured during contrast phase.  
 
Parameters to analyse 
 
 
Plaque morphology analysis: 
 
Each visible plaque is to be classified in terms of echogenicity at standard imaging, 
according to well-established criteria:  
Class I: uniformly echolucent 
Class II: predominantly echolucent 
Class III: predominantly echogenic 
Class IV: uniformly echogenic 
Class V: extensive calcification with acoustic shadowing 
 
Stenosis 
 
The degree of stenosis is to be measured according to European Carotid Surgery Trial 
(ECST) criteria and according to blood flow velocities. This parameter was acquired 
at time of scanning. Ratio can be calculated using Xcelera measurement tool as listed 
in carotid protocol.   
 
Side Succes
s % 
Image 
time 
IMT 
(mm) 
True 
Diamete
r 
(cm) 
Residual 
Diameter 
(cm) 
% 
Stenosis 
  A: Right 
  P: 
   
  A: Left 
  P: 
   
Side PSV (cm/s) 
CCA                  
ICA 
EDV (cm/s) 
CCA                      
ICA 
ICA/CCA 
Ratio 
Right      
Left      
Lesion
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Contrast image analysis:  
 
In contrast-enhanced images, all the plaques appear dark and hypoechoic while the 
adventitia still appears as a bright echogenic line. Moving bright spots within the 
plaque or on its adventitial side are considered to represent the contrast agent’s bubble 
signal coming from plaque neovascularization.  Fixed echogenic spots are considered 
to be strong tissue acoustic reflectors.  
Plaque neo- vascularization should categorized as follows:  
                 Grade 0: No contrast within Plaque 
                 Grade 1: No bubbles within the plaque or bubbles confined to  
                                plaque adventitial side and/or shoulder; 
                 Grade 2: bubbles reaching plaque core and/or extensive contrast-  
                                agent enhancement throughout the plaque.  
 
Carotid Contrast Ultrasound SOP References: 
1. Stefanadis C, Vlachopolous C, Karayannacos P. et al. Effect of vasorum flow 
on structure and function of the aorta in experimental animals. Circulation 
1995; 921:2669-78. 
2. Moreno PR, Purushothaman KR, Fuster V, et al. Plaque neovascularization is 
increased in ruptured atherosclerotic lesions of human aorta: implications for 
plaque vulnerability. Circulation 2004; 110:2032-8. 
3. Hennerici MG. The unstable plaque. Cer Dis. 2004; 17:17–22. 
4.  Fleiner M, Kummer M, Mirlacher M, Sauter G, Cathomas G, Krapf R, 
Biedermann BC. Arterial neovascularization and inflammation in vulnerable 
patients: early and late signs of symptomatic atherosclerosis. Circulation. 
2004; 110:2843–2850. 
5. Warburton L, Gillard J. Functional imaging of carotid atheromatousplaques. J 
Neuroimaging. 2006; 16:293–301. 
6. Feinstein SB. Contrast ultrasound imaging of the carotid artery vasa vasorum 
and atherosclerotic plaque neovascularization. J Am Coll Cardiol. 2006; 
48:236 243. 
7.  Vicenzini E, Ricciardi MC, Puccinelli F, Lenzi GL. Cerebral perfusion in a 
high- grade glioma evaluated with sonographic contrast pulse sequencing 
technology. J Ultrasound Med. 2006; 25:1215–1218. 
8. Bartels E, Henning S, Wellmer A, Giraldo-Velasquez M, Kermer P. 
Evaluation of cerebral perfusion deficit in stroke patients using new 
transcranial contrast imaging CPS technology–preliminary results. Ultraschall 
Med. 2005; 26:478 – 486.  
9. Widder B, Paulat K, Hackspacher J, Hamann H, Hutschenreiter S, Kreutzer C, 
Ott F, Vollmar J. Morphological characterization of carotid artery stenosis by 
ultrasound duplex scanning. Ultrasound Med Biol. 1990; 16:349 –354. 
10. European Carotid Surgery Trialists’ Collaborative Group. Randomised trial of 
endarterectomy for recently symptomatic carotid stenosis: final results of the 
MRC European Carotid Surgery Trial (ECST).Lancet.1998; 351: 1379 –1387. 
11. Sabeti S, Schillinger M, Mlekusch W, Willfort A, Haumer M, Nachtmann T, 
Mullner M, Lang W, Ahmadi R, Minar E. Quantification of internal carotid 
artery stenosis with duplex US: comparative analysis of different flow velocity 
criteria. Radiology. 2004; 232:431– 439. 
100 
12. Eva B.Color-Coded Duplex Ultrasound of the Cerebral Vessels. Atlas and 
Manual. Stuttgart, Germany: Schattauer Ed; 70 –71.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
101 
Appendix 4: Carotid Contrast Ultrasound Data Sheet 
 
CUPNASA Study: Data analysis                                         plasma code: 
 Anthony Jaipersad                                                            Scan code: 
                                                                                              Flow code: 
 
Patient ID:                                                                        Date of Analysis: 
Date of Scan: 
  
 
Plaque morphology:  Right:                                     Left: 
     0. No lesion I. Uniformly Echolucent         II. Predominantly Echolucent       III. 
Predominantly Echogenic            IV. Uniformly Echogenic         V. Extensive 
Calcification/Shadowing 
 
 
AVV:                           Right:                                      Left: 
  Grade 0: no contrast within plaque           
 Grade 1: microbubbles within plaque or bubbles confined to adventitial side                      
 Grade 2: clear visible microbubbles reaching plaque core or enhanced plaque. 
 Grade 5: no comment 
 
 Image Quality:             Right:                                      Left: 
                                                                   Excellent/good/Fair 
Comments: 
 
Signature of Reviewer:                                                                              Printed Name:  
 
 
 
 
 
 
Side Succes
s % 
Image 
time 
IMT 
(mm) 
True 
Diamete
r 
(cm) 
Residual 
Diameter 
(cm) 
% 
Stenosis 
  Right 
  
P:    
  Left 
  
P:    
Lesion
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Appendix 5: Flow Cytometry Protocol 
Flow Cytometry Protocol 
 
Sign in- FC logbook and laboratory logbook 
Pipettes required –  2-20ul (grey) 
   5-40ul (red) 
   40-200 ul (yellow) 
   200-1000ul (purple) 
   10-100ul and 100-1000ul digital  
 
1. Sign laboratory logbook 
2. Centrifuge 4 blood tubes (2 x citrate, 1 x serum, 1 x EDTA)- 2860RPM for 15 
mins 
3. Label tubes 1-3 and additional tube for absolute count (AC) 
4. Place Antibodies from ‘master mix’ 
Tube  1 22.5ul (red) 
2 22.5ul (red) 
3 22.5ul (red) 
AC 12.5ul (grey)- place on opposite side to count beads 
 
5. Add blood to tubes 
 
AC 
Take 10-100ul digital pipette 
 Set to 2 x 50ul 
 Withdraw blood then expel by pressing reset, take up blood once again 
 Wipe pipette tip to remove excess blood 
Eject 50ul into AC tube 
Replace tube top 
  
  
Tubes 1-3 
Take 100-1000ul digital pipette 
Set to 10 x 100ul 
Withdraw blood then expel by pressing reset, take up blood once again 
Wipe pipette tip to remove excess blood 
Eject 100ul into tubes 1-3 (1 press)  
 
Replace rest of blood into EDTA blood tube 
 
6. Vortex all samples (level 3) 
7. Place samples in dark for 15 minutes (taken from when last sample prepared) 
8. Prepare Flow Cytometer  
 
Turn on FC and after few seconds computer. 
Empty waste and refill with 360ml distilled water and 40ml bleach (ensure no bleach 
on gloves) 
Fill machine with Facs flow to appropriate level (level of indentation) 
Pressurize 
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Press LOW/PRIME with the arm closed (distilled water in place)- once PRIME light 
goes off press once more 
Remove distilled water and place ‘top right’ on rack 
Insert Facsclean- open 1 minute, closed 5 minutes- then remove and place ‘top left’ 
on rack- set FC on ‘high/run’ 
Insert PBS- 1 minute open, 5 minutes closed 
 
9. Use time to prepare ELISA samples for storage 
10. Lysing  
Purple pipette (200-1000ul)  
 2 x 1000ul i.e.. 2mls Facslyse tubes 1-3 
 450ul AC tube 
10. Place tops on tubes and vortex 
11. Place AC in dark for 15 minutes- after which sample ready to be processed 
Place tubes 1-3 in centrifuge- leave for 10 minutes before spinning for 5 
minutes (300RPM) 
12. Use time to finish ELISA preparation if needed 
 
Prepare Computer 
Calibration- 1000ul (purple pipette) of Facs flow- tubes A &B 
Place 1 drop of Blue top and white top into A and B, Green, red, pink top into B 
only 
Calibration- open Facscomp icon- enter initials, accept, run 
Vortex tube A and B- insert A followed by B 
 
13. Remove tubes from centrifuge- Decant 1-3 
14. Add PBS- Large pipette with PBS nozzle 
3mls into tubes 1-3 
15. Replace tops and vortex 
16. Place tubes 1-3 in centrifuge- 300RPM for 5 minutes 
17. For AC- purple pipette (200-1000) 
Add PBS 750ul x 2  
Vortex 
 
      Finish computer preparation 
      Open CellQuest icon 
      Close box, don’t save 
FILE- open document, data 1, Mon protocols, Mon no wash 
ACQUIRE- connect to cytometer 
CYTOMETER- choose instrument settings, Mon no wash, Set, Done 
Drag small symbol up and ‘unclick’ setup 
Change directory- e.g. NST-SP 241109 
Change file name- e.g. MonAC NST1-1 SP 
 
18. Place AC into cytometer and press acquire (press acquire on top bar, press 
counters)- once finished, print 
19. Remove tubes 1-3 from centrifuge 
20. Decant all tubes 
21. Re-suspend with yellow pipette- 100ul PBS 
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Before running tubes 1-3- Empty FC waste and add more facsflow 
To run tubes 1-3 
On computer- Close box, don’t save 
FILE- open document, choose Mon wash Luke Ben 
CYTOMETER- Install settings open; choose Luke Ben, set, done 
WINDOWS- show browser, click Monocyte Tony- clear panel, load tubes from 
Mon Tony 
Change directory and file name as before 
22. Vortex and run tubes 1-3, changing file on each sample (1, 2, 3 etc.)- print 
after each 
23. At end- Facsclean open 1 min, closed 5 mins, during which time clean up! 
24. Distilled water open 1 min, closed 5 mins 
25. Press standby and low 
26. Depressurize- shutdown computer 
27. After 5 minutes- close flow cytometer by green button 
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Appendix 6: SOP 198 Monocytes 
STANDARD OPERATING PROCEDURE 198 
 
Absolute count of monocyte subsets and assessment of surface  
marker expression on them by Flow Cytometry 
SOP written by Dr Eduard Shantsila & Dr A. Blann 
 
N.B. Use of the flow cytometry is forbidden  
Without having been officially trained 
 
Required pre-training 
 
4. SOPs on venepuncture and on  good clinical practice 
 
5. SOP 171 – Operation of the Bayer Advia 
 
6. SOP 193 – General operation of the flow cytometer 
 
 
Contents 
 
Introduction   Page 1 
 
Materials and suppliers Page 2 
 
Detailed Method  Page 4 
 
 
1. Introduction 
 
Monocytes are circulating blood cells that participate in innate immunity and 
inflammatory response as well as in other processes such as angiogenesis, formation 
of tissue macrophages and dendritic cells, etc. Several monocyte subsets can be 
discriminated, such as on the basis of surface expression of: 
 
• CD14 (lipopolysaccharide receptor)  
• CD16 (Fcγ receptor III), and  
• CCR2 (the receptor for monocyte chemoattractant protein [MCP-1]). 
 
This SOP describes enumeration and characterisation monocyte subsets of: 
 
• CD14+CD16- monocytes (about 85%),  
• CD14+CD16+ monocytes (about 5%) and  
• CD14lowCD16+ monocytes (about 10%): and all by expression of CCR2 
 
However, multiple analyses are possible because the FC and its lasers can 
accommodate four different fluorochromes: 
 
• FL1 is set up for AF488 
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• FL2 is set up for PE 
• FL3 is set up for Per-CP-Cy5.5 
• FL4 is set up for APC 
 
This means that other cell surface and intracellular molecules can be probed, 
assuming a relevant antibody conjugated to a useable fluorochrome can be sourced. It 
follows that various sub-protocols can be derived. Therefore this SOP comes in three 
stages:  
 
(a) An absolute white blood cell count that gives a monocyte count is 
necessary to ensure results are fed back mathematically so the number of each type of 
cell per ml of venous blood can be determined.  
 
(b) The assessment of surface expression of various receptors i.e. CD14 and 
CD16 on the surface of monocyte subsets – performed with ‘lyse-and-wash’ protocol. 
This part of protocol can be done without CCR2 so that two of four channels are 
available of FACSCalibur flow cytometer (i.e., PE- and APC-channels) can be used 
for evaluation of other parameters. This section will be generic for all subsequent sub-
protocols.   
 
(c) The profile of these sub-protocol parameters may vary depending on the 
aim of a sub-project and may include receptors mediating different but specific 
functions of monocytes. These include potential roles in…. 
 
• Platelet marker (CD42a) to detect monocyte –platelet aggregates (MPAs). 
This sub-SOP was part validated for intra-assay CV on 14th January 2010 
 
• Intracellular I-kappa-kinase-β (IKKβ). This sub-SOP was part validated for 
intra-assay CV and isotype control on 11th February SOP 20 
 
• Angiogenesis (as can be marked by molecules such as VEGF receptors 1 and 
2, CXCR4 [stromal cell-derived factor-1], CD34) 
 
•  Inflammatory responses (interleukin-6 receptor, Toll-like receptor 4) 
 
• Differentiation and migration (receptors to adhesion molecules ICAM-1 and 
VCAM-1), i.e. integrin β2/CD18,  integrin α4/CD49d 
 
• Scavenger receptors (CD204, CD163)  
 
 
It follows from the above that considerable thought must be directed towards these 
complex assays, especially as different antibodies may be conjugated to the same 
fluorochrome.  
 
2. Materials and Supplier contact details: 
 
2.1 General reagents and disposables 
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1) BD “FACS Flow” Running solution [Becton Dickinson, Catalogue No. 
342003] 10L containers. 
2) BD “FACS Clean” Cleaning Solution [Becton Dickinson, Catalogue No. 
340345]  
3) 3 ml BD Falcon tubes [Becton Dickinson, Catalogue No. 352054] 
4) BD Lysing solution [Becton Dickinson Catalogue No. 349202] 
5) Sterile Phosphate Buffered Saline solution, 0.5L bottles [Invitrogen Ltd, 
Catalogue No 20012-068] 
6) BD TruCount tubes [Becton Dickinson Catalogue No. 340334] 
7) Clear pipette tips [Alpha Laboratories Limited Catalogue No FR1250 1250ul 
Fastrak Refill NS]  
8) Yellow pipette tips [[Alpha Laboratories Limited Catalogue No FR1200 200ul 
Fastrak Refill NS]  
9) Pipettes required  2-20ul (grey top)       5-40ul (red top) 
    40-200 ul (yellow top)  200-1000ul 
(purple top) 
    10-100ul and 100-1000ul digital  
 
2.2 Antibodies - Generic 
 
10) CD14-PE conjugated monoclonal antibody [R&D Systems Europe Ltd, Cat 
No. FAB3832P] – this is for the absolute counts (AC) of cells only – not the 
mastermixes (see below) 
11) CD14-PerCP-Cy5.5 conjugated monoclonal antibody [Becton Dickinson 
Catalogue No. 550787] – for mastermixes (see below) 
12) CD16-Alexa Fluor 488-conjugated monoclonal antibody [AbD Serotec, 
Oxford, UK, Cat No. MCA2537A488] 
13) CCR2-APC conjugated monoclonal antibody [R&D Systems Europe Ltd, Cat 
No. FAB151A] 
 
2.3 Antibodies – Sub-protocols: for example: 
 
 
14) CD42a-PerCP conjugated monoclonal antibody [Becton Dickinson, Catalogue 
No. 340537]  
15) IKKbeta-APC conjugated monoclonal antibody 50µg/ml - 100 tests [Becton 
Dickinson, Catalogue No. 551920] 
16) VEGFR1-APC conjugated monoclonal antibody (R&D Systems Europe Ltd 
Catalogue No. FAB321A)  
17) VEGFR2 (KDR, CD309)-APC conjugated monoclonal antibody [R&D 
Systems Europe Ltd Catalogue No. FAB321A] 
18) CD34-PE conjugated monoclonal antibody (Becton Dickinson, Catalogue No. 
555822) 
19) TLR4 (CD284)-PE conjugated monoclonal antibody [R&D Systems Europe 
Ltd Catalogue No. FAB14781P]  
20) IL-6 receptor α-APC conjugated monoclonal antibody [R&D Systems Europe 
Ltd Catalogue No. FAB227A]  
21) Mac-1-PE conjugated monoclonal antibody (CD11/CD18, receptor for ICAM-
1) [R&D Systems Europe Ltd Catalogue No. FAB1730P]  
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22) Integrin α4/CD49 complex-APC conjugated monoclonal antibody [R&D 
Systems Europe Ltd Catalogue No. FAB1354A]  
23) CD163-APC conjugated monoclonal antibody [R&D Systems Europe Ltd 
Catalogue No. FAB1607A]  
24) CXCR4-PE conjugated monoclonal antibody (CD184) [R&D Systems Europe 
Ltd Catalogue No. FAB170P]  
 
 
3.1 General Preparation 
 
3.1.1 Lysing solution (kept on the shelf in flow cytometry room at room temperature).   
 
Make from 50ml concentrate 10x FACS Lysing Solution (kept at room temperature). 
Dilute with 450ml distilled water in ½ litre bottle. This solution should not be used if 
it is older than a month (kept at room temperature). When this is made up the operator 
must ensure that date is put on the bottle. 
 
3.1.2. Mastermixes (MMs)  
 
These are made up to define the particular subject of the sub-protocol.  There are 
separate tubes for different sub-projects. All MMs are composed to 100 ul of blood, 5 
ul CD16-AF488 and 2.5 ul CD14-PerCP-Cy5.5. Sub-MMs for individual sub-
protocols then have other antibodies in addition. For example….. 
 
MM1: IL6-R-APC and TLR4-PE 
 
3.1.3. Time from blood sample collection by aseptic venepuncture (see appropriate 
guidelines) to beginning of sample preparation should be less 30 min, and must not be 
more than 60 min. 
 
3.2 Blood sample preparation 
 
3.2.1. Place EDTA blood sample on rotator. 
3.2.2. Label tubes 1-5 and additional tube for absolute count (AC) 
3.2.3. Place Antibodies from ‘mastermixes’: 
 
Tube 1 - 22.5ul (red top) 
Tube 2 - 22.5ul (red top) 
Tube 3 - 22.5ul (red top) 
Tube 4 - 27.5ul (red top) 
Tube 5 - 22.5ul (red top) 
 
AC tube - 12.5ul (grey top) - place on opposite side to count beads. Do not touch 
the pellet!!!! If this happened – change the tube 
. 
3.2.4. Add blood to tubes  
 
a) Absolute count tube: 
- Take 10-100ul digital pipette 
- Set to 2 x 50ul 
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- Withdraw blood then expel by pressing ‘RESET’, take up blood once again 
- Wipe pipette tip to remove excess blood 
- Eject 50ul into AC tube – keep the tip well above the metal retainer. Do not touch 
pellet!!!  
- Replace tube top 
 
b) MM Tubes 1-5 
- Take 100-1000ul digital pipette 
- Set to 10 x 100ul 
- Withdraw blood then expel by pressing reset, take up blood once again 
- Wipe pipette tip to remove excess blood 
- Eject 100ul into tubes 1-5 (1 press)  
- Replace rest of blood into EDTA blood tube (keep it in case you need to repeat the 
procedure) 
3.2.5. Vortex all samples (speed 3 for 3 sec) [what speed and duration?] 
3.2.6. Place samples in dark for 15 minutes (taken from when last sample prepared) 
 
 
3.3 Start up procedure [See SOP 195 on General Operation] 
 
- Turn on FC and after few seconds computer. 
- Empty waste (right container) and refill with 360ml distilled water and 40ml bleach 
(ensure no bleach on gloves) 
- Fill machine with left container by Facsflow to appropriate level (level of 
indentation) 
- Pressurize 
- Press LOW/PRIME with the arm closed (distilled water in place)- once PRIME light 
goes off press once more 
- Remove distilled water and place ‘top right’ on rack 
- Insert Facsclean tube (2ml of Facsclean) – opened arm 1 minute, closed 5 minutes - 
then remove and place ‘top left’ on rack- set FC on ‘high/run’ 
- Insert a tube with sterile PBS - 1 minute open arm, 5 minutes closed arm 
 
 
3.4. Further sample preparation 
 
3.4.1. Red blood cell lysing  
- Use purple pipette (200-1000ul) 
- Put 2mls of Facslyse in Tubes 1-5 
- Put 450ul in AC tube 
- Place tops on tubes and vortex (speed 3 for 3 sec) 
- Place AC tube in dark for 15 minutes- after which add 1.5 mls of PBS, vortex - 
sample ready to run 
- Place tubes 1-5 in centrifuge- leave for 10 minutes before spinning for 5 minutes 
(300RPM) 
- Remove tubes 1-5 from centrifuge, decant, add 3 mls of PBS, replace tops, vortex, 
spin again - 300RPM for 5 minutes 
- Decant supernatant, resuspend in 100 ul of PBS – sample ready to run 
 
3.5. Sample acquisition 
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3.5.1. Absolute count 
- Run FacsComp if you are first user of the flow cytometer during the day 
- Press CellQuest icon 
- ‘FILE’ – ‘Open document’ – ‘Data 1’ – ‘Mon protocols’ – ‘Mon no wash’ 
- ACQUIRE – ‘Connect to cytometer’ 
- CYTOMETER – ‘Choose instrument settings’ – ‘Mon no wash’ – ‘Set’ – ‘Done’ 
- Change appropriate directory to save flow data 
- Change file name 
- Place AC into cytometer and press ‘Acquire’ (press ‘Acquire’ on top bar, press 
‘Counters’) - once finished, print 
3.5.2. Expression of surface markers 
- ‘FILE’ – ‘Open document’ - choose – ‘Mon wash Luke/Ben’ 
- CYTOMETER – ‘Instrument settings’ – ‘Open’ - choose ‘Mon wash Luke/Ben’ – 
‘Set’ – ‘Done’ 
- ‘WINDOWS’ – ‘Show browser’ 
- Change directory and file name as before 
- Vortex and run tubes 1-5, changing file on each sample (1, 2, 3 etc.)- print after each 
 
Absolute counts of monocyte subsets are performed automatically by flow cytometry  
software and calculated as number of count beads in tube x number of monocytes 
collected/(number of collected count beads x volume of blood, μl).  
 
For example: typical number of count beads in a tube – 50000 
Number of CD14+CD16- monocytes collected – 5000 
Number of collected count beads – 10000 
Volume of blood to be used – 50 μl. 
Absolute count of CD14+CD16- monocytes will be: 50000 x 5000/(10000 x 50) = 
500 cells/μl 
 
 
3.6. Shut-down procedure   [See SOP 195 on General Operation] 
 
1. In this section we re-use tubes 1 and 2 with distilled water and FACS clean 
respectively. 
 
2. Install FACS Clean tube 2 over the SIP needle. Press button ‘High’ and ‘Run’ 
on the panel. Leave the support arm out at 90 degrees for approximately 1 
minute.  This cleans the outer portion of the aspiration sheath.  The fluid will 
be rapidly aspirated, so ensure that the tube doesn’t empty completely. 
 
3. Now replace the side arm under the Falcon tube and allow to run for 
approximately 5 minutes.  This cleans the inner portion of the aspiration 
sheath and the FACS machine itself. 
 
4. Repeat steps 2 and 3 with the distilled water tube 1.  Once step 3 is complete, 
Leave the sheath in falcon tube 1 containing distilled water and press 
‘STANDBY’. 
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5. Open the reservoir draw and depressurize the machine by moving the “Vent 
Valve” toggle switch to the up/rear position.  The machine will hiss as it 
depressurizes. 
 
6. Leave the machine on for a further 5 minutes to allow the laser lamp to cool.  
Turning the machine off prematurely will result in the lamp cracking. 
 
7. Finally power down the FAC-Calibur (green button) and Apple Mac. 
 
8. Clean. 
 
9. Note: * IF THE SYSTEM IS TO BE USED AGAIN ON THE SAME DAY… 
 
LEAVE THE SYSTEM ON STANDBY and then 
 
DEPRESSURISE THE SYSTEM. 
 
4. Interpretation of the results 
 
Part 1 of the analysis is the number is the number of monocytes in classes 1, 2 and 3, 
as defined by CD14, C16 and CCR2 and is generic to all sub-protocols. This data will 
be in all operators spreadsheets. Separation of monocytes from other blood cells and 
debris is based of three gates (see Appendix 1). Gate 1 employs region ‘Mon’ to 
include all monocytic cells on the basis of FSC/SSC characteristics. Gate 2 employs 
region ‘Monos’ to exclude granulocytes from analysis. Gate 3 employs region ‘NK 
Lymph’ to exclude them from analysis. Monocyte subsets are defined as:  
 
Mon1 – CD14+CD16-CCR2+ cells 
Mon2 – CD14+CD16+CCR2+ cells and  
Mon3 – CD14lowCD16+CCR2+.  
 
Absolute counts of monocyte subsets are performed automatically by flow cytometry 
software and calculated as number of count beads in tube x number of monocytes 
collected/(number of collected count beads x volume of blood, μl).  
 
The protocol employs a ‘single platform’ approach (i.e., full blood count is not 
needed for obtaining absolute count). The number of count beads in the pellet has 
been included in protocol formulas (by Dr. Eduard Shantsila). Absolute count of 
monocyte subsets and monocyte-platelet aggregates (per μl of blood) is performed 
automatically and represented on both screen of flow cytometer and printout. See 
statistics of monocyte count and immunophenotypic characteristics obtained from 
healthy volunteers in table 1. 
 
The percentage of cells expressing PE-conjugated markers (MAC-1, TLR4, CXCR4, 
VEGF receptor 1, CD34 is estimated as proportion of cells positive to these markers 
(upper right plus lower right quadrants on correspondent plots). 
 
The percentage of cells expressing APC-conjugated markers (Integrin α4/CD49 
complex, CD163, IL6-receptor, KDR, CD204) is estimated as proportion of cells 
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positive to these markers (upper left and upper right quadrants on correspondent 
plots). 
 
 
SOP 198 Monocyte Table 
 
Comparative characteristics of monocyte subsets – expected results 
 
 
    
Parameter Mon1 Mon2 Mon3 
 
Absolute count, cell /μl 
 
360.1±87.0 
 
24.5±14.8 
 
38.9±12.7 
Mon, %* 
 
84.6±5.77 5.90±3.40 9.51±3.74 
MPA, cell /μl 37.0±10.9 3.68±2.45 4.59±1.69 
MPA, %** 
 
10.4±2.30 16.0±5.65 11.95±2.56 
CD204, %*** 24.5±14.9 56.9±16.7 61.1±14.29 
CD163, %*** 
 
98.6±1.27 99.7±0.32 70.3±13.7 
Integrin β2/CD18, %*** 100 (100-100) 100 (100-100) 99.9 (99.8-100) 
Integrin α4/CD49d, %*** 
 
74.7 (59.8-82.2) 94.7 (91.1-96.7) 99.1 (98.2-99.4) 
CXCR4, %*** 91.0 (79.3-96.2) 95.6 (92.0-97.9) 51 (42.9-58.9) 
VEGF receptor 1, %*** 
 
18.2 (14.5-52.0) 69.6 (62.3-85.3) 28.3 (20.75-33.23) 
KDR, %*** 5.00 (3.38-7.23) 8.25 (5.65-10.9) 2.80 (2.23-4.58) 
CD34, %*** 
 
0.45 (0.2-1.0) 1.45 (0.83-3.3) 2.40 (1.8-3.7) 
TLR4, %*** 18.4 (14.3-32.2) 63.2 (46.4-75.2) 21.4 (18.4-29.9) 
IL6 receptor, %*** 100 (99.9-100) 100 (99.9-100) 96.3 (93.5-97.9) 
 
 
Data is mean (SD) or median (IQR). Mon1 – CD14+CD16-CCR2+ monocytes, Mon2 
– CD14+CD16+CCR2+ monocytes, CD14+CD16+CCR2- monocytes, MPA – 
monocyte-platelet aggregates, VEGF – vascular endothelium growth factor, TLR4 – 
Toll-like receptor-4, IL6 – interleukin 6 * Per cent of total monocyte count, **Per 
cent of MPA compared to the whole  monocyte subset, ***Per cent of positive cells 
within a monocyte subset.  
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Appendix 7: SOP 66 VEGF 
 
STANDARD OPERATING PROCEDURE 66 
 
Vascular Endothelial Growth Factor (VEGF) 
 
ELISA developed by Funmi Belgore and Andrew Blann, 1997 and 1998. This 
SOP was updated by  Balu Balakrishnan August 2007 
 
Introduction Page 1 
Materials Page 2 
Method Page 6 
 
1. INTRODUCTION 
 
Synopsis: 
 
Vascular endothelial growth factor (VEGF) is a multi-functional peptide capable of 
inducing angiogenesis and may have effects on endothelial integrity. It has been 
implicated in neovascularisation in adult pathophysiology. This ELISA uses 
commercial antibody and will require about 4-6 hours to complete. 
  
Brief Method: 
 
1. Coat microtitre plate with 112 μl of primary antisera l in 20 ml PBS buffer for 2 
plates overnight in the fridge. 
 
2. Wash, block with 100 μl /well of 5% Marvel (1g in 20mls PBS-T for 2 plates) for 
1 hour at RT. 
 
3. Wash, add 100 μl of neat plasma, or neat tissue culture fluid, and recombinant 
standards for 2 hours at RT. Standards are double diluted down the plate. Use 
fresh tips for each sample. 
 
4. Wash, add 112 μl of biotinylated anti-human VEGF antibody in 20 ml PBS tween 
for 90 minutes at RT. 
 
5. Wash, add Streptavidin (100μl/well) for 45 minutes at RT. 
 
6. Wash, add 100 μl substrate (Solutions A and B) .Blue colour develops well with 
in 20 to 30 minutes 
 
7. Stop with 50 μl/well acid. Colour goes yellow. Read at 450 nm.  
 
Expected values: 
 
Data usually not normally distributed. Controls generally have median values of about 
30-50 pg/ml (but IQR may be over 200pg/ml) Patients’ median values generally 100 
to over 200 pg/ml. Again, wide IQRs. 
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2. MATERIALS 
 
2.1 Coating the plate with 1% AB 
 
The plates are coated with 20ml of 1%AB.To make up the buffer use 20ml of PBS 
(1X), liquid 20012-068 from Life technologies and add 112 μl of 1%AB from the 
stock solution. 
 
2.2 Primary Antiserum 
 
2.2.1 The primary antisera is goat anti-human VEGF antibody.  
 
Supplier, storage and location 
 
From R&D systems, Tel: 01235 529 449, Fax: 01235 533 420.  
Catalog Number: DY293B Duoset kit 
 
Reconstitute vial with 1ml PBS and aliquot out to 112μl aliquots and store in the –70 
freezer until use. 
 
Add 20mls of pbs to give 20μg/20mls or 1μg/ml, i.e. the working concentration 
(enough for 2 plate) 
 
 
2.3 Microtitre plates 
 
2.3.1 Flat-bottomed 96 well microtitre plates (Immunlon 2)  
 
Supplier, storage and location 
 
Thermo Life Sciences, Basingstoke. Telephone 01256 817 282. 
 
2.4  Yellow and Blue Tips 
.  
2.4.1 Yellow and blue tips  
 
Supplier, storage and location 
 
Appleton Woods Ltd, Lindon House, Heeley Road, Selly Oak, Birmingham B29 
6EN. 
Tel 0121 472 7353, Fax 0121 414 1075. Freefax orderline 0800 387 462, Website 
www.appletonwoods.co.uk.  
 
Our account number DUD 001, we have various discounts for various goods. 
 
Tips stored at RT in plastic bags/boxes under the desk in the main lab.  
 
2.5 Wash Buffer 
 
To make this up, you need 
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2.5.1 Phosphate buffer saline tablets. Sigma catalogue number P 4417. Buy in lots 
of 50 or 
100 tablets. Kept on the shelves on the right hand side. 
 
2.5.2 Tween 20. Sigma Catalogue number P 1379. Order in 100 ml lots. Also kept 
on the  
shelves on the far right hand side. 
 
2.5.3 Distilled water. 
 
Supplier 
 
Sigma  – Aldrich, 0800 717181. Our account number is 782274. They will ask for 
your name (use mine) and order number (use your initials). 
 
Method/storage/supplier 
 
To one litre of water, add 5 tablets and 0.5 ml Tween (use a blue tip and 
micropipette). Place on rotamixer with stir bar, wait until tablets have dissolved. We 
generally make up several litres at a time. Stored at room temperature on the 
rotamixer. 
 
n.b. Generally, make up 2, 3 or more litres in one batch. 
 
Biohazard/COSHH  
 
(n.b. this is not an official assessment!) nil unless you eat/drink a few kilos/litres. 
Wash off spills with water. Otherwise maintain good laboratory practice. 
 
2.6 Secondary Antiserum 
 
2.6.1 The secondary antisera is biotinylated goat anti-human VEGF polyclonal 
antiserum (conjugated to biotin).  
 
Supplier, storage and location 
 
From R&D systems, Tel: 01235 529 449, Fax: 01235 533 420.  
Catalog Number: DY293B Duoset kit 
 
Reconstitute the vial with 1ml of PBS-0.1%BSA (gives stock of 18μg/ml of stock) 
and aliquot into 112μl aliquots and store in the –70 freezer until use.  
 
Add 20mls of PBS-T to give 1μg /10mls or 500ng/ml (enough for 1 plate).  
 
2.7 Steptavidin-HRP conjugate 
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Streptavidin binds to biotin, thus amplifying the signal. HRP = horse radish 
peroxidase. Obtain from R&D Systems, Abingdon, as for the antibodies and rVEGF 
standard.  
 
From R&D systems, Tel: 01235 529 449, Fax: 01235 533 420 
Catalogue number: DY998 
 
The order consists of five small glass vials, each with 1 ml fluid. Store in the 4o 
Fridge. Do not freeze. However: Extravidin peroxidase can also be obtained from 
Sigma: Catalogue number: E 2886. Add 10μl of extravidin peroxidase to 10mls of 
PBS-T for 1 plate.  
 
2.8 Substrate 
 
This is/are Solutions A and B from R&D Systems. 
 
Biohazard/COSHH  
 
(n.b. this is not an official assessment!) nil unless you eat/drink a few kilos/litres. 
Wash off spills with water. Otherwise maintain good laboratory practice. 
 
2.9 Standards 
 
Supplier/storage 
From R&D systems, Tel: 01235 529 449, Fax: 01235 533 420.  
Catalog Number: DY293B Duoset kit 
 
The stock solution of rVEGF standard was prepared by adding 500ul of Pbs Buffer 
.Then aliquoted out into vials containing 33ul each so as to attain a top standard of 4 
ng when made up to one ml with Pbs. 
 
2.10 Stop Solution 
 
1 mol/L hydrochloric acid. No need to dilute. 
 
Supplier/ Storage 
 
Sigma, Catalogue number 920-1. Order in lots of 1 gallon ( = 3.8 L). 
 
Biohazard/COSHH  
(n.b. this is not an official assessment!) Considerable. Do not get on skin/clothes. 
Wash off spills with water. Otherwise maintain good laboratory practice. 
 
3. METHOD 
 
Step 1 Coating microtitre plates 
 
Using a micropipette and a yellow tip, transfer the 112 μL of primary antibody 
aliquots (2.2) to approximately 20 mls Pbs buffer (2.1) and, using an eight-channel 
micropipette with yellow tips, apply 100 μL to each well of the micro titre plate (2.3). 
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Place in lunch box with lid and label. Incubate in the fridge overnight or two hours at 
room temperature. 
 
Step 2 Wash and block 
 
Using the eight-channel washing manifold (Sigma), wash out the unbound antiserum 
with three lots of >250 μL PBS/tween (2.5). Blot out on tissue paper between each 
step. 
 
Using the 8-channel pipette, add 100 μl of 5% Marvel (2.9) into each well and 
incubate at RT for 1 hours. 
 
Step 3. Samples of plasma, serum or tissue culture fluid AND standards (need to 
made up fresh each time 
 
Wash again as above. 
 
Thaw plasma/serum samples in warm water in the sink, but never for long, just to take 
the chill off. Even from –70oC, small aliquots are quick to thaw.  
 
100μl of neat plasma/culture medium added to each well. CHANGE TIPS EACH 
SAMPLE 
 
The Standard Curve [correct at 6.2.2007] 
 
The standard consisting of a small amount of rVEGF has been pre-aliquoted and 
stored in the top compartment of the -70oC freezer in the box labelled VEGF.  
 
Stock 
Current top batch is 33 ul of fluid with 4 ng of protein per vial. Therefore take one of 
these and make it up to one ml for 4 ng\ml working concentration.  
 
Working 
Place top standard of 200 ul in wells of columns 11 and 12 of row A in two plates. 
This will be 4 ng/mL. Use the leftover 100 ul in the wells for double dilution on the 
plates. 
 
Take  
Of this leftover, take 100 ul in the wells below i.e. 11B and 12 B mix well continue 
the same all the way to the bottom of the plate. Double dilute the standards to the next 
but last wells that is 11g and 12 g maintain 11h and 12h as blanks (free of VEGF). 
 
Replace the plates in plates in the lunch box as before and incubate for 2 hours at RT. 
 
Discard all left over eppendorf vials. 
 
Step 5 – Wash and Secondary (Detection) Antibody 
 
Wash as above. 
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The secondary Ab should have been aliquoted and stored in the –70 (2.6). Transfer 
the secondary to 20mls of PBS-T (make sure it is well mixed) and add 100μl into 
each well with 8-channel pipette. Incubate at RT for ninety minutes. 
 
Step 6 – Wash and Conjugate 
 
Wash again as above. 
 
Using a micropipette and a yellow tip, add 100μl of Steptavidin-HRP to 
approximately 20mls of PBS-T (2.10) and, using an eight-channel micropipette with 
yellow tips, apply 100 μL to each well. Place back in the lunch box with lid and label 
and incubate on the bench for 30 minutes. 
 
n.b. discard the tips immediately: a mere 1 molecule of contaminating enzyme will 
work on your substrate.  
 
Step 7 – Wash Again 
 
As 3.2, but be very thorough at this stage. Being slack here means the blanks will be 
positive. 
 
Step 8 – Colour Development 
 
This is R&D Systems solutions A and B. Get them out of the ‘fridge in plenty of time 
to warm up e.g. on the bench on in warm water. Mix them before use 
 
Add 100 μL substrate in a controlled manner, and then the acid at the same speed in 
the same direction (e.g.. both right to left).  It may be that you have to stop the 
reaction at the start of the first plate as soon as you have finished adding substrate to 
the end of the second plate.  
 
Exactly when to stop the reaction is a learned skill. Generally, when you can 
differentiate a gradient between all the standards and the blanks are still blank. 
 
Wait till the standards develop .The observer must be able to differentiate between the 
last two standards. 
 
n.b. if the reaction is slow the most likely reason is that the substrate buffer is out of 
pH  
 
 
Step 9 – Reading and Calculation 
 
9.1 Put the ELISA reader on to warm up (see separate instructions on the wall 
above the  
machine). Ensure the wavelength is 450 nm. 
 
9.2 Construct a standard curve using 3 log graph paper from the standards and 
read off your pg/ml from the optical densities.  
 
119 
 
Step 10 – Disposal: See GLP document 
 
All tips and leftover whole plasma to go in sharps bin. Microtitre plates to be emptied 
down a sink, then washer out with tap water, then put in yellow bins. 
 
 
SOP SIGNED OFF BY ANDREW BLANN (Date) 
 
 
MASTER PAPER COPY KEPT BY RUBY STONE. 
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Appendix 8: SOP 19 Tie 2 ELISA 
 
STANDARD OPERATING PROCEDURE 19 
 
Tie-2 ELISA 
 
Written by Balu Balakrishnan 2013 
 
1. INTRODUCTION 
 
Synopsis: 
 
Vascular endothelial growth factor (VEGF) is a multi-functional peptide capable of 
inducing angiogenesis and may have effects on endothelial integrity. It has been 
implicated in neovascularisation in adult pathophysiology. This ELISA uses 
commercial antibody and will require about 4-6 hours to complete. 
  
Brief Method: 
 
8. Coat microtitre plate with 112 μl of primary antisera l in 20 ml PBS buffer for 2 
plates overnight in the fridge. 
 
9. Wash, block with 300 μl per well of reagent diluent for 1 hour at RT. 
 
10. Wash, add 10 μl of neat plasma to 90 μl of reagent diluent, or neat tissue culture 
fluid, and recombinant standards for 2 hours at RT. Standards are double diluted 
down the plate. Use fresh tips for each sample. 
 
11. Wash, add 112 μl of Detection Antibody in 20 ml of reagent diluent for 2 hours at 
RT 
 
12. Wash, add Streptavidin (100μl/well) for 20 minutes at RT. 
 
13. Wash, add 100 μl substrate (Solutions A and B) .Blue colour develops well with 
in 20 to 30 minutes 
 
14. Stop with 50 μl/well acid. Colour goes yellow. Read at 450 nm.  
 
Range:156 - 10,000 pg/mL  
 
 2. MATERIALS 
 
2.1 Coating the plate with 1% AB 
 
The plates are coated with 20ml of 1%AB.To make up the buffer use 20ml of PBS 
(1X), liquid 20012-068 from Life technologies and add 112 μl of 1%AB from the 
stock solution. 
 
2.2 Primary Antiserum 
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The mouse anti-human Tie-2 antibody.  
 
Supplier, storage and location 
 
From R&D systems, Tel: 01235 529 449, Fax: 01235 533 420.  
Catalog Number: DY5159 Duoset kit 
 
Reconstitute vial with 1ml PBS and aliquot out to 112μl aliquots and store in the –70 
freezer until use. 
 
Add 20ml of PBS (1X), liquid 20012-068 from Life technologies for the working 
concentration enough for 2 plate. 
 
2.3 Microtitre plates 
 
2.3.1 Flat-bottomed 96 well microtitre plates . 
 
Supplier, storage and location 
 
Thermo Life Sciences, Basingstoke. Telephone 01256 817 282. 
 
2.4  Yellow and Blue Tips 
.  
Yellow and clear tips  
 
Supplier, storage and location 
Alpha Laboratories Limited 
Tel – 02380483000 
 
2.5 Wash Buffer 
 
To make this up, you need 
 
Phosphate buffer saline tablets. Sigma catalogue number P 4417. Buy in lots of 50 or 
100 tablets. Kept on the shelves on the right hand side. 
 
Tween 20. Sigma Catalogue number P 1379. Order in 100 ml lots. Also kept on the  
shelves on the far right hand side. 
Distilled water. 
 
Supplier 
 
Sigma  – Aldrich, 0800 717181.  
 
Method/storage/supplier 
 
To one litre of water, add 5 tablets and 0.5 ml Tween (use a blue tip and 
micropipette). Place on rota mixer with stir bar, wait until tablets have dissolved. We 
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generally make up several litres at a time. Stored at room temperature on the 
rotamixer. 
 
n.b. Generally, make up 2, 3 or more litres in one batch. 
 
Biohazard/COSHH  
 
(n.b. this is not an official assessment!) nil unless you eat/drink a few kilos/litres. 
Wash off spills with water. Otherwise maintain good laboratory practice. 
 
2.6 Secondary Antiserum 
 
2.6.1 The secondary antisera is biotinylated mouse anti-human Tie-2 polyclonal 
antiserum (conjugated to biotin).  
 
Supplier, storage and location 
 
From R&D systems, Tel: 01235 529 449, Fax: 01235 533 420.  
Catalog Number: DY5159 Duoset kit 
 
Reconstitute the vial with 1ml of PBS-0.1%BSA and aliquot into 112μl aliquots and 
store in the –70 freezer until use.  
 
Add 20mls of PBS-T to give 1μg /10mls or 500ng/ml (enough for 1 plate).  
 
2.7 Steptavidin-HRP conjugate 
 
Streptavidin binds to biotin, thus amplifying the signal. HRP = horse radish 
peroxidase. Obtain from R&D Systems, Abingdon, as for the antibodies and Tie-2 
standard.  
 
From R&D systems, Tel: 01235 529 449, Fax: 01235 533 420 
Catalogue number: DY998 
 
 
 
2.8 Substrate 
 
This is/are Solutions A and B from R&D Systems. 
 
Biohazard/COSHH  
 
(n.b. this is not an official assessment!) nil unless you eat/drink a few kilos/litres. 
Wash off spills with water. Otherwise maintain good laboratory practice. 
 
2.9 Standards 
 
Supplier/storage 
 
From R&D systems, Tel: 01235 529 449, Fax: 01235 533 420.  
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Catalog Number: DY5159 Duoset kit 
 
The stock solution of Tie-2 standard was prepared by adding 500ul of Pbs Buffer. 
Then aliquoted out into vials containing 43.5ul each so as to attain a top standard of 
10 ng when made up to one ml with Pbs. 
 
2.10 Stop Solution 
 
1 mol/L hydrochloric acid. No need to dilute. 
 
Supplier/ Storage 
 
Sigma, Catalogue number 920-1. Order in lots of 1 gallon ( = 3.8 L). 
 
Biohazard/COSHH  
(n.b. this is not an official assessment!) Considerable. Do not get on skin/clothes. 
Wash off spills with water. Otherwise maintain good laboratory practice. 
 
 
3. METHOD 
 
Step 1 Coating microtitre plates 
 
Using a micropipette and a yellow tip, transfer the 112 μL of primary antibody 
aliquots to approximately 20 mls Pbs buffer and, using an eight-channel micropipette 
with yellow tips, apply 100 μL to each well of the micro titre plate. Place in a box 
with lid and label. Incubate in the fridge overnight or two hours at room temperature. 
 
Step 2 Wash and block 
 
Using the eight-channel washing manifold (Sigma), wash out the unbound antiserum 
with three lots of >250 μL PBS/tween . Blot out on tissue paper between each step. 
 
Using the 8-channel pipette, add 300 μl of Reagent diluent into each well and 
incubate at RT for 1 hours. 
 
Step 3. Samples of plasma, serum or tissue culture fluid AND standards (need to 
be made up fresh each time) 
 
Wash again as above. 
 
Thaw plasma/serum samples in warm water in the sink, but never for long, just to take 
the chill off. Even from –70oC, small aliquots are quick to thaw.  
 
10μl of neat plasma to 90μl of Reagent diluent added to each well. CHANGE TIPS 
EACH SAMPLE 
 
The Standard Curve  
 
Stock 
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Current top Std is 43.5 ul of fluid with 10ng of protein per vial. Therefore take one of 
these and make it up to one ml for 10 ng\ml working concentration.  
 
Working 
Place top standard of 200 ul in wells of columns 11 and 12 of row A in two plates. 
This will be 10 ng/mL. Use the leftover 100 ul in the wells for double dilution on the 
plates. 
 
Take  
Of this leftover, take 100 ul in the wells below i.e. 11B and 12 B  mix well continue 
the same all the way to the bottom of the plate. Double dilute the standards to the next 
but last wells that are 11g and 12 g maintain 11h and 12h as blanks (free of VEGF). 
 
Replace the plates in plates in the box as before and incubate for 2 hours at RT. 
 
Discard all left over eppendorf vials. 
 
Step 5 – Wash and Secondary (Detection) Antibody 
 
Wash as above. 
 
The secondary Ab should have been aliquoted and stored in the –70 or in the duoset 
box. Transfer the secondary to 20mls of PBS-T (make sure it is well mixed) and add 
100μl into each well with 8-channel pipette. Incubate at RT for 2 hours. 
 
Step 6 – Wash and Conjugate 
 
Wash again as above. 
 
Using a micropipette and a yellow tip, add 100μl of Steptavidin-HRP to 
approximately 20mls of PBS and, using an eight-channel micropipette with yellow 
tips, apply 100 μL to each well. Place back in the box with lid and label and incubate 
on the bench for 30 minutes. 
 
n.b. discard the tips immediately: a mere 1 molecule of contaminating enzyme will 
work on your substrate.  
 
Step 7 – Wash Again 
 
As 3.2, but be very thorough at this stage. Being slack here means the blanks will be 
positive. 
 
Step 8 – Colour Development 
 
This is R&D Systems solutions A and B. Get them out of the ‘fridge in plenty of time 
to warm up e.g. on the bench on in warm water. Mix them before use 
 
Add 100 μL substrate in a controlled manner, and then the acid at the same speed in 
the same direction (e.g.. both right to left).  It may be that you have to stop the 
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reaction at the start of the first plate as soon as you have finished adding substrate to 
the end of the second plate.  
 
Exactly when to stop the reaction is a learned skill. Generally, when you can 
differentiate a gradient between all the standards and the blanks are still blank. 
 
Wait till the standards develop .The observer must be able to differentiate between the 
last two standards. 
 
n.b. if the reaction is slow the most likely reason is that the substrate buffer is out of 
pH  
 
Step 9 – Reading and Calculation 
 
9.3 Put the ELISA reader on to warm up (see separate instructions on the wall 
above the  
machine). Ensure the wavelength is 450 nm. 
 
9.4 Construct a standard curve using 3 log graph paper from the standards and 
read off your pg/ml from the optical densities.  
Step 10 – Disposal: See GLP document 
 
All tips and leftover whole plasma to go in sharps bin. Microtitre plates to be emptied 
down a sink, then washer out with tap water, then put in yellow bins. 
 
 
 
SOP SIGNED OFF BY ANDREW BLANN (Date) 
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Appendix 9: Published Papers 
 
 
Jaipersad AS, Shantsila A, Lip GY, Shantsila E. Expression of monocyte subsets 
and angiogenic markers in relation to carotid plaque neovascularization in 
patients with pre-existing coronary artery disease and carotid stenosis. Annals of 
Medicine. 2014; 46(7): 530-8. 
 
Jaipersad AS, Lip GYH, Silverman S, Shantsila E. The Role of Monocytes in 
Angiogenesis and Atherosclerosis. Journal of the American College of Cardiology. 
2014; 63(1): 1-11. 
 
Jaipersad AS, Shantsila E, Blann A, Lip GYH. The Effects of Statin Withdrawal on 
Monocyte Subsets. European Journal of Clinical Investigation. 2013; 43(12): 1307-
1313. 
 
Jaipersad AS, Shantsila A, Silverman S, Lip GYH, Shantsila E. Evaluation of 
Carotid Plaque Neovascularization Using Contrast Ultrasound. Angiology. 2012; 
64(6): 447-450. 
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